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ZUSAMMENFASSUNG 
Vitamin-D-Versorgung und Risiko einer Anämie bei Patienten mit kardiovaskulärer 
Erkrankung 
Das Vorliegen eines Vitamin-D-Mangels sowie einer Anämie ist bei Patienten mit 
kardiovaskulärer Erkrankung (CVD) allgemein verbreitet. Beide Erkrankungen sind 
unabhängige Risikofaktoren für gesteigerte Morbidität und Mortalität. Epidemiologische 
Studien weisen auf eine inverse Assoziation zwischen der Vitamin-D-Versorgung und dem 
Risiko einer Anämie bei verschiedenen Personengruppen hin. Erste nicht-randomisierte 
Interventionsstudien zeigen einen Anstieg des Hämoglobin (Hb)-Spiegels durch die Gabe von 
Vitamin-D-Metaboliten. Jedoch werden noch immer adäquat designte, randomisierte 
kontrollierte Studien (RCT) mit Vitamin D benötigt, um zu klären, ob die Gabe von Vitamin D 
einen positiven Effekt auf das Vorliegen einer Anämie hat. Sollte sich dies bestätigen, könnte 
eine Vitamin-D-Supplementierung eine vielversprechende präventive oder therapeutische 
Option sein, um die Prävalenz eines Vitamin-D-Mangels sowie die Anämie-Prävalenz zu 
senken. Folglich war das Ziel der vorliegenden Arbeit 1) die Untersuchung der Assoziationen 
zwischen Vitamin-D-Metaboliten und Anämie bei Patienten mit CVD und zu ermitteln, ob 2) 
eine tägliche Vitamin-D-Supplementierung bei Patienten mit CVD die Hb-Werte verbessern 
und somit das Risiko einer Anämie verringern kann. 
In zwei Querschnittsstudien (KAPITEL EINS und KAPITEL ZWEI) konnten signifikante, 
unabhängige, inverse Assoziationen zwischen den Vitamin-D-Metaboliten 25-Hydroxyvitamin 
D (25OHD) und 1,25-Dihydroxyvitamin D (1,25[OH]2D) und dem Risiko einer Anämie bei 
herzchirurgischen Patienten sowie Patienten, die für eine Koronarangiographie vorgesehen 
waren, gezeigt werden. In beiden Studien konnte eine stärkere Assoziation zwischen dem 
Vorliegen einer Anämie und niedrigen 1,25(OH)2D Spiegeln (<40 pmol/l) als defizitären 
25OHD Werten (<30 nmol/l) nachgewiesen werden. In zwei Sekundäranalysen zweier RCTs 
wurden die Effekte eines täglichen Vitamin D3 Supplements auf die Hb-Werte und das Risiko 
einer Anämie im Vergleich zu Placebo in Patienten mit Bluthochdruck für acht Wochen 
(2,800 IE täglich; KAPITEL DREI) und in herzinsuffizienten Patienten für 36 Monate (4,000 IE 
täglich; KAPITEL VIER) untersucht. Beide Studien zeigten, dass eine tägliche Vitamin-D-
Supplementierung zu keiner Verbesserung der Hb-Werte bei Patienten mit CVD führt. 
Vergleichbare Ergebnisse wurden in Subgruppenanalysen bei Patienten mit initialen 25OHD 
Werten <30 nmol/l und bei Patienten mit initialer eGFR <60 mL/min/1.73 m2 gefunden. Die 
Vitamin-D-Gabe konnte die Anämie-Prävalenz bei Patienten mit Bluthochdruck nicht 
signifikant verändern (7,5% Baseline vs. 7,5% Studienende), wohingegen die Anämie-
Prävalenz bei herzinsuffizienten Patienten in der Vitamin-D-Gruppe um 12,9% anstieg. 
Zusammenfassend spricht sich diese Arbeit, trotz der vielversprechenden Ergebnisse der 
Querschnittsstudien, gegen einen klinisch relevanten positiven Effekt von Vitamin-D-
Supplementen auf den Hb-Spiegel bei Patienten mit CVD aus. Da niedrige 1,25(OH)2D Spiegel 
stärker mit dem Risiko einer Anämie assoziiert sind als defizitäre 25OHD Spiegel und erste 
Interventionsstudien mit der Gabe von 1,25(OH)2D vielversprechende Ergebnisse zeigten, 
sollten zukünftige RCTs die Gabe aktiver Vitamin-D-Metabolite bei anämischen und Vitamin-
D-defizitären Patienten genauer untersuchen. 
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SUMMARY 
Vitamin D status and risk of anemia in patients with cardiovascular disease 
Vitamin D deficiency and anemia are prevalent in patients with cardiovascular disease (CVD), 
and both are independent risk factors for increased morbidity and mortality. Epidemiological 
studies suggest an inverse association between vitamin D status and anemia risk in several 
populations. Earlier non-randomized intervention studies reported an increase in hemoglobin 
(Hb) values by administration of vitamin D metabolites. However, adequately powered, 
randomized controlled trials (RCT) with vitamin D are still warranted to assess whether vitamin 
D has beneficial effects on anemia. If confirmed, vitamin D supplementation could be a 
promising preventive or therapeutic option to decrease the prevalence of vitamin D deficiency 
and anemia. Thus, the overall aim of this thesis was 1) to determine the associations between 
vitamin D metabolites and anemia in patients with CVD and 2) to determine if daily vitamin D 
supplementation can improve Hb levels and therefore anemia risk in CVD patients. 
Two cross-sectional studies (CHAPTER ONE and CHAPTER TWO) showed significant 
independent inverse associations between the vitamin D metabolites 25-hydroxyvitamin D 
(25OHD) and 1,25-dihydroxyvitamin D (1,25[OH]2D) and anemia risk in cardiac surgical 
patients and patients referred for coronary angiography. In both studies, the association of 
anemia was stronger with low circulating 1,25(OH)2D levels (<40 pmol/l) than it was with 
deficient circulating 25OHD levels (<30 nmol/l). In two secondary analyses of RCTs the effects 
of a daily vitamin D3 supplement on Hb levels and anemia risk versus placebo were examined 
in hypertensive patients for eight weeks (2,800 IU daily; CHAPTER THREE) and in heart failure 
patients for 36 months (4,000 IU daily; CHAPTER FOUR). Both investigations indicate that a daily 
vitamin D supplement does not improve Hb values in patients with CVD. Comparable results 
were shown in the subgroups of patients with initial 25OHD levels <30 nmol/l and in patients 
with initial eGFR values <60 mL/min/1.73 m2. In hypertensive patients, vitamin D treatment did 
not influence anemic status significantly (7.5% baseline vs. 7.5% study termination), whereas 
in patients with heart failure anemia status significantly increased by 12.9% in the vitamin D 
group. 
In conclusion, despite the promising results of the cross-sectional studies, this thesis argues 
against Hb-improving effects of vitamin D3 supplements that are of clinical relevance in patients 
with CVD. However, since 1,25(OH)2D concentrations show a stronger independent 
association with anemia risk than 25OHD levels and first interventional studies using 
1,25(OH)2D administration showed promising results, future studies should explore the 
administration of active vitamin D metabolites in anemic and vitamin D deficient patients in 
more detail.  
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Vitamin D is a fat soluble vitamin with two dominant forms: vitamin D2 (ergocalciferol) and 
vitamin D3 (cholecalciferol). For humans, there are three ways to achieve adequate levels of 
vitamin D supply [1-3]: 
 through diet (vitamin D2 and vitamin D3) 
 through supplements (only vitamin D3 supplements are available in Germany)  
 and through skin exposure to solar ultraviolet (UV) B radiation (wavelength 290-315 
nm). 
When the skin is exposed to UVB radiation, the liver-derived precursor 7-dehydrocholesterol 
is converted to pre-vitamin D, which in turn isomerizes to vitamin D [4]. The extent of this 
endogenous vitamin D synthesis is influenced by different factors like latitude and seasons. In 
Europe, the endogenous skin synthesis contributes up to 90% of the total human vitamin D 
status in June and July [5]. However, the endogenous synthesis may be completely missing in 
January. Therefore, dietary intake of vitamin D comprises 10% to 100% of circulating levels of 
vitamin D, depending on the season. Vitamin D2 is naturally present in fungi, such as 
mushrooms and yeast. Vitamin D3 is found in food of animal origin such as eggs and oily fish 
e.g. eel, herring, and salmon. 
Once in the circulation, vitamin D is predominantly (~88%) transported by the vitamin D-binding 
protein (DBP) [6]. The remaining ~12% is loosely bound to albumin, and only ~0.03% of 
25OHD is found in its free form [6,7]. The biologically inactive vitamin D is then converted by 
a hepatic hydroxylase (25-hydroxylase [CYP2R1-hydroxylase]) into 25-hydroxyvitamin D 
(25OHD). In a second hydroxylation, 25OHD is converted mainly in the kidney into its active 
hormonal form 1,25-dihydroxyvitamin D (1,25[OH]2D) by a 1α-hydroxylase (CYP27B1-
hxdroxylase). This endocrine production of 1,25(OH)2D is tightly controlled by parameters of 
bone and mineral metabolism, e.g. parathyroid hormone (PTH) and the phosphaturic hormone 
fibroblast growth factor (FGF)-23 [1]. While PTH stimulates the 1α-hydroxylation, FGF-23 and 
1,25(OH)2D itself inhibit this enzymatic reaction. Major endocrine 1,25(OH)2D actions include 
regulation of the bone and mineral metabolism by regulating calcium and phosphate 
homeostasis. The active vitamin D can also act in a paracrine and autocrine fashion because 
1α-hydroxylase expression has been reported in several extrarenal cells, including cells of the 
cardiovascular system [8]. 
The unbound active vitamin D can enter target cells and interact with the ligand-binding domain 
of the cytosolic vitamin D receptor (VDR) [9,10]. The expression of the VDR has been identified 
in almost all human tissues. Directly or indirectly, 3% of the human genome is regulated by the 
vitamin D endocrine system and the number of genes regulated by 1,25(OH)2D is still growing 
[11].  
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Degradation of 1,25(OH)2D and other vitamin D metabolites is initiated by 24-hydroxylation 
(24-hydroxylase [CYP24A1-hydroxylase]). This enzymatic process, which can be induced by 
VDR activation itself, can thereby prevent vitamin D intoxication as part of an autoregulatory 
loop [8].  
 
Figure 1:  Human metabolism of Vitamin D (adapted from [12]) 
 
The best indicator for defining human vitamin D status is the circulating 25OHD level [13], 
because it is the major circulating vitamin D metabolite that best reflects vitamin D supply from 
all sources, e.g. skin synthesis, dietary and supplemental intake [14]. As noted before, 
circulating 25OHD levels are influenced by many different factors like geographic factors 
(latitude and altitude) and individual factors (skin pigmentation, outdoor activities, clothing, 
dietary habits, sunscreen use and body mass index) [15-19].  
To this day, the optimal 25OHD concentration for maximizing the health benefits of vitamin D 
is still being debated [7]. Various cut-offs regarding the optimal vitamin D ranges have been 
proposed in the scientific community. The Institute of Medicine (IOM) classifies values between 
50-125 nmol/l as being adequate [20]. This recommendation is based on the fact that the IOM 
committee found 25OHD levels >50 nmol/l to be needed for good bone health for practically 
all individuals and that serum levels of 50 nmol/l are sufficient to meet the vitamin D 
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requirements in 97.5% of the general population. In detail, the IOM classifies vitamin D values 
<30 nmol/l as deficient, 30-49.9 nmol/l as insufficient, 50-125 nmol/l as adequate and >125 
nmol/l as potentially harmful. However, since vitamin D deficiency has been associated with a 
large number of conditions additionally to its classical effects on bone health, 
recommendations regarding higher cut-offs have been proposed. An international expert panel 
has recommended a target 25OHD range of 75-100 nmol/l [21]. Of note, this recommendation 
concerns adult patients with, or individuals at risk for, classical applications of vitamin D such 
as osteoporosis, chronic kidney disease (CKD) and endocrinopathies. In addition, these 
recommendations apply to adult patients >18 years at risk for diseases in which the role of 
vitamin D is emerging, e.g. autoimmune diseases, cancer and cardiovascular disease (CVD) 
[21]. The Endocrine Society Practice Guidelines also define sufficient 25OHD levels as being 
above 75 nmol/l to maximize the effect of vitamin D on calcium, bone and muscle metabolism 
[22]. Again, the Task Force supports its argument with numerous epidemiological studies 
suggesting that 25OHD levels >75 nmol/l may have additional health benefits such as reducing 
the risk of common cancers, autoimmune and infectious diseases, type 2 diabetes mellitus and 
CVD [22]. However, according to the German Nutrition Society (DGE), the evidence regarding 
the well-known associations between vitamin D supply and falls and fractures is the only 
evidence to be regarded as ʻconvincingʻ. Additionally, the DGE sees ʻlikelyʼ evidence regarding 
all-cause mortality among the elderly. For other diseases such as cancer, type 2 diabetes 
mellitus, hypertension and CVD, there is either ʻprobableʼ evidence that there is no association 
with the supply of vitamin D or the evidence regarding an inverse association or lack of an 
association with vitamin D supply was considered to be ʻpossibleʼ or ʻinsufficienctʼ [23]. Based 
on these findings, the DGE considers 25OHD levels of ≥50 nmol/l an indicator of an optimal 
vitamin D status. In conclusion, there is broad agreement to prevent and treat 25OHD levels 
<50 nmol/l [24]. 
Vitamin D deficiency is claimed as a significant worldwide health problem [25]. Hagenau et al. 
[26] reported a global 25OHD level of 54 nmol/l, which is close to the insufficiency range. In a 
systematic review of 195 studies in 44 different countries, 37.3% of the studies reported mean 
values below 50 nmol/l [27]. In the European Union, 13% and 40.4% of individuals were found 
to have 25OHD concentrations <30 nmol/l and <50 nmol/l, respectively [28]. A national health 
survey in German adults showed that mean serum 25OHD level was 45.6 nmol/l [29] with 
61.6% of the individuals having serum 25OHD levels <50 nmol/l. Compared to healthy controls, 
various groups of patients are at a higher risk of being vitamin D deficient. In Germany, 
approximately 25% of the all-cause patients even have 25OHD values <30 nmol/l [30]. In 
cardiac surgical patients, the prevalence of 25OHD values <30 nmol/l is between 15% and 
38% [31-33]. Regarding heart failure patients, the prevalence varies between 56% and 87.8% 
for 25OHD values <50 nmol/l [34-36] and between 28% and 66.7% for 25OHD values even 
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below 25 nmol/l [37,38]. Short-term solar UVB exposure and/or use of oral supplementation 
are effective methods for improving vitamin D status. The German, Austrian and Swiss 
Societies for Nutrition (D_A_CH) recommend a daily intake of 20 µg (800 International Units 
[IU]) vitamin D for children, adolescents and adults when endogenous synthesis is missing. In 
contrast, the median vitamin D intake of adults living in Germany is 2-4 µg [23]. 
According to the World Health Organization (WHO), anemia is considered a condition in which 
the number of red blood cells or the oxygen-carrying hemoglobin (Hb) is insufficient to meet 
physiological needs and is defined as an Hb concentration less than 13 g/dL for men and less 
than 12 g/dL for women. With an estimated prevalence of 24.8%, it affects nearly one out of 
four of the global population [39]. The prevalence varies by several clinical characteristics: 
Older age, female gender, race and the occurrence of several diseases (e.g. heart failure, 
renal impairment, diabetes mellitus) have a profound influence on prevalence estimates [40-
43]. In patients undergoing cardiac surgery the prevalence of anemia varies between 22.0% 
and 54.4% [44-46]. In heart failure patients, the prevalence rises up to 67.0% [47]. Of note, the 
prevalence correlates with the severity of the heart failure. In new-onset heart failure patients, 
the prevalence of anemia occurs only in 17.3% [48]. 
A growing body of evidence underscores the independent impact of anemia on a variety of 
clinical, functional and economic indicators [49]. In the elderly and various groups of patients 
with chronic diseases such as hemodialysis, heart failure, cardiac and non-cardiac surgery, 
anemia is an independent risk factor for increased morbidity and mortality. In several studies, 
anemia was associated with a 20% to 50% increased mortality risk in heart failure patients [50-
52]. In cardiac surgical patients, preoperative anemia was significantly associated with 
infections [53,54], stroke [44,54], renal failure [44,54], prolonged ventilatory support [53,54], 
intensive care unit and in-hospital stay [45,55] as well as in-hospital and all-cause mortality 
[44,53,54]. Of note, in patients with heart failure, a 1-g/dL increase in Hb was associated with 
a 14.2% reduction in risk of hospitalization and a 15.8% reduction in mortality risk [56]. 
Therefore, treatment of anemia can improve patients outcome [49]. Current anemia treatment 
strategies include administration of erythropoietin (EPO) and other erythropoiesis-stimulating 
agents (ESAs), intravenous iron therapy, concurrent treatment with ESA and iron as well as 
blood transfusions. However, the use of blood transfusions is accompanied by several risks. 
In detail, blood transfusion is an independent risk factor for several clinical complications 
including prolonged ventilator support [45], increased length of hospital stay [57], infection [58] 
and mortality [59]. Therefore, other preventive or therapeutic options to decrease the 
prevalence of anemia are warranted. 
There is evidence from several observational studies that indicate an inverse association 
between vitamin D status and anemia risk in several populations [60-68], including patients 
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with CVD, e.g. heart failure patients [34] and patients scheduled for cardiac surgery [69]. In 
heart failure patients, mean Hb values were significantly reduced in the lower tertiles of both 
vitamin D metabolites (25OHD [<18 nmol/l] and 1,25(OH)2D [<40 pmol/l]). The odds ratios (OR) 
for anemia of the lowest tertiles of 25OHD and 1,25(OH)2D were 2.69 (1.46-5.00) and 4.08 
(2.18-7.62) compared with their respective highest tertiles (>32 nmol/l; >70 pmol/l) [34]. In 
cardiac surgical patients, the ORs for anemia in the groups with severe (<12.5 nmol/l) and 
moderate (12.5-29.99 nmol/l) vitamin D deficiency were 1.49 (1.04-2.12) and 1.24 (1.01-1.52), 
respectively, compared with patients with vitamin D levels of 50-100 nmol/l. Sensitivity 
analyses showed a stronger association when the reference category was restricted to patients 
with 25OHD levels of 75-100 nmol/l (1.70 [1.09-2.63] and 1.41 [1.02-1.96] for severe and 
moderate vitamin D deficiency, respectively) [69]. Interestingly enough, there is some evidence 
that circulating levels of 1,25(OH)2D is a better predictor of anemia than circulating 25OHD 
[34]. However, sufficient data on the relationship between Hb levels and the active vitamin D 
metabolite 1,25(OH)2D is lacking. 
In line with the observational studies, first non-randomized interventional studies in patients 
with CKD demonstrated an increase in Hb concentration after 12 months of intravenous 
1,25(OH)2D administration and therefore improved control of anemia with reduced need for 
EPO [70,71]. In another study in hemodialysis patients, intravenous administration of 
1,25(OH)2D decreased the weekly needed EPO dose by 50% [72]. The supplementation of 
high-dose vitamin D2 (50,000 IU monthly) was associated with ESA-dose reductions in 
hemodialysis patients. Yet, mean Hb levels remained unchanged [73,74]. However, these 
earlier studies have some limitations since they included only small numbers of patients and 
no control group.  
Several experimental studies point to a relationship between low vitamin D levels and the 
development of anemia: (i) 1,25(OH)2D may stimulate erythropoiesis in red blood precursor 
cells by increasing EPO sensitivity. In addition, 1,25(OH)2D can upregulate proliferation of 
hematopoietic progenitor cells.[75,76] (ii) 1,25(OH)2D is able to suppress the release of tumor 
necrosis factor-α [77,78] and interleukin-6 [77] and may therefore reduce the inflammatory 
milieu, leading to anemia of chronic disease.[62] (iii) Vitamin D may influence folate and iron 
absorption by increasing intestinal proton-coupled folate transporter.[79,80] The renal 
activation of 25OHD into 1,25(OH)2D is catalyzed by a cytochrome P450-dependent ferrodoxin 
reductase.[81] 
Therefore, studies investigating the relationship between anemia risk with both vitamin D 
metabolites, 25OHD and 1,25(OH)2D, as well as adequately powered randomized controlled 
trials (RCT) with vitamin D supplementation are warranted to assess the association between 
vitamin D status and anemia risk and to proof if the association is causal. 
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The objective of this thesis was to answer the following questions: 
 
1) Is there an independent association of the vitamin D metabolites 25OHD and 
1,25(OH)2D with Hb levels and anemia risk in different groups of patients with CVD? 
 
2) Does a vitamin D supplementation improve Hb levels and therefore anemia control in 
different groups of patients with CVD? 
 
To answer these questions, four clinical studies were performed:  
Two cross-sectional studies (CHAPTER ONE and CHAPTER TWO) aimed to answer question 1) 
by investigating the associations between the vitamin D metabolites 25OHD and 1,25(OH)2D 
and anemia risk in cardiac surgical patients and patients referred for coronary angiography. 
In two secondary analyses of RCTs, question 2) was tried to be answered (CHAPTER THREE 
and CHAPTER FOUR). For that, the effect of a daily vitamin D supplementation versus placebo 
was investigated in hypertensive patients for eight weeks (2,800 IU/d) and in heart failure 
patients for 36 months (4,000 IU/d). 
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Abstract 
Background: Preoperative anemia is considered an independent risk factor of poor clinical 
outcome in cardiac surgical patients. Low vitamin D status may increase anemia risk. 
Methods: We investigated 3,615 consecutive patients scheduled for cardiac surgery to 
determine the association between preoperative anemia (hemoglobin [Hb] <12.5 g/dL) and 
circulating levels of the vitamin D metabolites 25-hydroxyvitamin D (25OHD) and 1,25-
dihydroxyvitamin D (1,25[OH]2D).  
Results: Of the study cohort, 27.8% met the criteria for anemia. In patients with deficient 
25OHD levels (<30 nmol/l) mean Hb concentrations were 0.5 g/dL lower than in patients with 
adequate 25OHD levels (50.0–125 nmol/l; P<0.001). Regarding 1,25(OH)2D, mean Hb 
concentrations were 1.2 g/dL lower in the lowest 1,25(OH)2D category (<40 pmol/l) than in the 
highest 1,25(OH)2D category (>70 pmol/l; P<0.001). In multivariable–adjusted logistic 
regression analyses, the odds ratios for anemia of the lowest categories of 25OHD and 
1,25(OH)2D were 1.48 (95%CI:1.19-1.83) and 2.35 (95%CI:1.86-2.97), compared with patients 
who had adequate 25OHD levels and 1,25(OH)2D values in the highest category, respectively. 
Anemia risk was greatest in patients with dual deficiency of 25OHD and 1,25(OH)2D 
(multivariable-adjusted OR = 3.60 (95%CI:2.40-5.40). Prevalence of deficient 25OHD levels 
was highest in anemia of nutrient deficiency, whereas low 1,25(OH)2D levels were most 
frequent in anemia of chronic kidney disease. 
Conclusion: This cross-sectional study demonstrates an independent inverse association 
between vitamin D status and anemia risk. If confirmed in clinical trials, preoperative 
administration of vitamin D or activated vitamin D (in case of chronic kidney disease) would be 
a promising strategy to prevent anemia in patients scheduled for cardiac surgery. 
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Introduction 
Anemia is a worldwide public health problem. With an estimated prevalence of 24.8%, it affects 
nearly one out of four of the global population [1]. The prevalence of anemia in patients 
undergoing cardiac surgery varies between 22.0% and 54.4% [2-5]. 
There is evidence from several observational studies that preoperative anemia is an 
independent predictor of poor clinical outcome in cardiac [2-4, 6-8] and non-cardiac [9] surgical 
patients. Different peri- and postoperative complications such as infections [3, 6, 7], stroke [2, 
7] and renal failure [2, 7, 10], as well as prolonged ventilatory support [3, 7] and intensive care 
unit and in-hospital stay [3, 8, 9], were significantly associated with preoperative anemia. In 
addition, preoperative anemia is an independent risk factor of in-hospital and all-cause 
mortality [2, 6, 7, 9]. 
It has recently been shown that 25-hydroxyvitamin D (25OHD) deficiency is independently 
associated with lower hemoglobin (Hb) levels and higher anemia risk in patients scheduled for 
cardiac surgery [5]. The association between vitamin D deficiency and anemia is supported by 
various observational studies in different groups of patients [11-14]. Data in end-stage heart 
failure patients also indicate that circulating levels of the active vitamin D hormone, 1,25-
dihydroxyvitamin D (1,25[OH]2D), is a better predictor of anemia than circulating 25OHD [14]. 
In line with these findings, first interventional studies in hemodialysis patients demonstrated an 
increase in Hb levels after intravenous administration of 1,25(OH)2D3, resulting in improved 
control of anemia [15, 16]. Experimental studies have provided evidence for potential 
mechanisms regarding how vitamin D may contribute to anemia prevention [17, 18]. Briefly, 
1,25(OH)2D may influence bone marrow by stimulating erythropoiesis in red cell precursor cells 
via increased erythropoietin (EPO) sensitivity. Moreover, 1,25(OH)2D has the capacity to up-
regulate proliferation of progenitor cells, independent of the presence of EPO.  
The present study therefore aimed to investigate the association of preoperative 25OHD and 
1,25(OH)2D levels with the risk of anemia in patients scheduled for cardiac surgery. 
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Subjects and Methods 
Patients 
For this cross-sectional study, we considered 3,852 adult patients who were scheduled for 
cardiac surgery at our institution between February 2012 and December 2013 (geographic 
latitude 52˚N). We excluded 237 patients with incomplete data sets, e.g. missing 25OHD 
levels, 1,25(OH)2D levels and/or Hb levels, leaving a total of 3,615 patients for data analysis. 
The vast majority of patients were Caucasians. This investigation is a secondary analysis of 
the CALCITOP-study which was approved by the Ethics Committee Ruhr University Bochum 
at Bad Oeynhausen, was registered at clinicaltrials.gov as NCT02192528, and was recently 
published [19]. Participants provided their written confirmed consent. All patient information 
was anonymized and de-identified prior to analysis. 
Study Design 
For analysis, we used routinely collected and filed demographic and clinical patient data 
(THGQIMS, Münster, Germany) and biochemical patient data (Lauris, SWISSLAB, Berlin, 
Germany). Blood samples were collected and analyzed on the last day before cardiac surgery. 
We assessed levels of 25OHD, 1,25(OH)2D and Hb, as well as other biochemical parameters 
(creatinine, C-reactive protein [CRP], leukocytes, erythrocytes, hematocrit [Htc], mean 
corpuscular volume [MCV], mean corpuscular hemoglobin [MCH], thrombocytes, red blood cell 
distribution width). In addition, we assessed patient characteristics like age, gender, season of 
blood sampling, body mass index, smoking, left ventricular ejection fraction [LVEF], 
concomitant diseases (myocardial infarction [MI], chronic obstructive pulmonary disease 
[COPD], stroke, hemofiltration, peripheral arterial occlusive disease [PAOD], hypertension, 
diabetes, hyperlipidemia) and medication use (diuretics, angiotensin-converting enzyme-
inhibitors, angiotensin receptor-blockers, aspirin, clopidogrel, glucocorticoids).  
Biochemical Analysis 
Circulating 1,25(OH)2D3 levels were measured by a liquid chromatography/tandem mass 
spectrometry method provided by Immundiagnostik (Bensheim, Germany). Since the detection 
limit of the method is 14 pmol/l, we considered values below this limit as 13.0 pmol/l. Circulating 
25OHD levels (sum of 25[OH]D2 and 25[OH]D3) were analyzed by the autoanalyzer Liaison 
(DiaSorin, Stillwater, MN, USA). The measuring range was between 10 and 375 nmol/l. Values 
below the detection limit of 10.0 nmol/l were considered 9.9 nmol/l. CRP and creatinine levels 
were measured using the Architect Autoanalyzer (Abbott, Wiesbaden, Germany). Estimated 
glomerular filtration rate (eGFR) was calculated using the Modification of Diet in Renal Disease 
[20]. Blood Hb, Htc, erythrocytes, leukocytes, thrombocytes, MCV and MCH were measured 
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by automated procedures using the Abbott CellDyn 3500 hematology analyzer (Abbott, 
Wiesbaden, Germany). According to earlier classifications [2, 5], Hb concentrations <12.5 g/dL 
were considered as anemic, which is the average threshold value of the World Health 
Organization’s gender-based definition (<13 g/dL in men and <12.0 g/dL in women). The 
following reference values were used for other hematological parameters: erythrocytes: males: 
4.5-6.9 1012/l, females: 4.0-5.2 1012/l; Htc: males: 41-53%, females: 36-46%; MCH: 26-34 pg 
Hb/erythrocytes; MCV: 80-94 μm3. Together with low Hb levels, low MCV values can be an 
indicator of iron deficiency, whereas high MCV values can be an indicator of folate and/or 
vitamin B12 deficiency [21]. Therefore, we used earlier approaches to classify anemia 
hierarchically according to subtypes [5, 22]: anemia because of nutritional deficiency (iron 
deficiency: MCV <80 μm3; folate or vitamin B12 deficiency: MCV: >94 μm3), anemia of chronic 
kidney disease (CKD; eGFR: <60 ml/min per 1.73 m2), anemia of inflammation (CRP >10 mg/l) 
and unexplained anemia if none of these subtypes were present. 
Statistics 
Categorical variables are reported as a percentage of observations. Continuous variables are 
presented as a mean and standard deviation. Clinical and demographic parameters of anemic 
and non-anemic patients were compared using Student´s t test, Chi-squared test and ANOVA. 
All continuous variables were normally distributed (Kolmogorov-Smirnov test). According to 
the Institute of Medicine [23], the following 25OHD cutoff values were used for classifying 
vitamin D status: deficiency (<30 nmol/l), inadequacy (30-49.9 nmol/l), adequacy (50-125 
nmol/l) and potentially harmful (>125 nmol/l). Based on earlier classifications (14, 24), 
1,25(OH)2D values were divided into three categories (<40 pmol/l; 40-70 pmol/l; >70 pmol/l).  
To assess the independent association of 25OHD and 1,25(OH)2D categories with anemia, we 
performed logistic regression analysis (unadjusted and multivariable-adjusted). Results are 
expressed as odds ratios (ORs) with a 95% confidence interval. We considered the groups 
with adequate 25OHD levels (50-125 nmol/l) and 1,25(OH)2D levels >70 pmol/l as a reference 
group. The following covariates were included in multivariable models: model 1: unadjusted 
data; model 2: adjusted for age, gender and season of blood sampling (winter: January through 
March; spring: April through June; summer: July through September; fall: October through 
December); model 3: model 2 plus adjustments for body mass index, smoking, LVEF, 
concomitant diagnoses (MI, COPD, stroke, hemofiltration, PAOD, hypertension, diabetes and 
hyperlipidemia) and medications (diuretics, angiotensin-converting enzyme-inhibitors, 
angiotensin receptor-blockers, aspirin, clopidogrel, glucocorticoids); model 4: model 3 plus 
adjustments for kidney function (eGFR in ml/min per 1.73 m2) and inflammatory processes 
(CRP in mg/dL). In sensitivity analysis, we also used the following 25OHD classification: <50 
nmol/l, 50-125 nmol/l and >125 nmol/l. We considered the P-values <0.05 as statistically 
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significant. P-values are two-sided. Analyses were performed using SPSS version 21.0 (SPSS, 
Inc., Chicago, IL, USA). 
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Results 
Of the study cohort, 26.1% were 25OHD deficient (<30.0 nmol/l), 35.4% had inadequate 
25OHD values (30-49.9 nmol/l), 36.7% had adequate 25OHD values (50-125 nmol/l) and 1.7% 
had values >125 nmol/l. Regarding 1,25(OH)2D, 29.4% had values below 40 pmol/l, 40.6% 
values between 40 and 70 pmol/l and 30.0% had values >70 pmol/l. Baseline characteristics 
of the study cohort are listed in Table 1, broken down by anemia status. Of the study cohort, 
27.8% met the criteria for anemia. Compared with non-anemic patients, circulating 25OHD and 
1,25(OH)2D levels were significantly lower in anemic patients. Anemic patients were 
significantly older, more frequently female but less often smokers than non-anemic patients. 
In addition, anemic patients had significantly lower LVEF values and suffered more often from 
COPD, hemofiltration, PAOD, diabetes and hyperlipidemia than non-anemic patients. In 
addition, anemia was associated with reduced Hb, Htc, MCV, MCH and erythrocyte values, 
but MCV, MCH and erythrocyte values were still within the respective reference range. CRP 
was significantly elevated in the anemic group. 
Tables 2 and 3 illustrate the hematological parameters broken down by 25OHD status and 
1,25(OH)2D categories, respectively. Anemia risk was greatest in the groups with the lowest 
25OHD and 1,25(OH)2D concentrations. In detail, mean Hb concentrations were 0.5 g/dL lower 
in patients with deficient levels of 25OHD levels (<30 nmol/l) than in patients with adequate 
25OHD levels (50.0–125 nmol/l; P<0.001). Regarding 1,25(OH)2D, mean Hb concentrations 
were 1.2 g/dL lower in patients in the lowest 1,25(OH)2D category (<40 pmol/l) than in the 
highest 1,25(OH)2D category (>70 pmol/l; P<0.001). Hematological parameters, such as 
erythrocytes, Htc, MCH and MCV, were all lowest in patients with low 1,25(OH)2D levels. MCV 
and MCH were lowest in patients with deficient 25OHD levels, whereas erythrocytes and Htc 
were lowest in patients with 25OHD levels >125 nmol/l. MCV differed significantly between 
25OHD categories, but not between 1,25(OH)2D categories. 
In Tables 4 and 5, the ORs for anemia are given by categories of 25OHD and 1,25(OH)2D. In 
the unadjusted model, the ORs for patients in the lowest categories of 25OHD and 1,25(OH)2D 
were significantly higher = 1.79 (95% CI: 1.49-2.15) and 3.73 (95% CI: 3.05-4.56), compared 
with the respective reference group. In the fully adjusted models, the ORs for anemia were 
attenuated, but remained significant. Compared with the respective reference group, the OR 
for the category of 25OHD deficient patients was = 1.48 (95% CI: 1.19-1.83) and was = 2.35 
(95% CI: 1.86-2.97) for the lowest 1,25(OH)2D category.  
In patients with dual deficiency of 25OHD and 1,25(OH)2D (n=336), the fully adjusted OR for 
anemia was compared with patients who had adequate 25OHD levels and 1,25(OH)2D levels 
in the highest category (n=438) = 3.60 (95% CI: 2.40-5.40; P<0.001). In sensitivity analysis, 
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the fully adjusted OR of patients with 25OHD values <50 nmol/l was = 1.21 (95% CI: 1.01-
1.45), compared with the reference group of 50 – 125 nmol/l.  
The prevalence of deficient 25OHD levels was highest in anemia of nutrient deficiency, 
whereas low 1,25(OH)2D levels were most frequent in anemia of CKD (Figures 1 and 2). 
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Table 1:  Characteristics of the study cohort by anemia status 
 Anemic  Non-anemic  P value 
 (<12.5 g/dl) (≥12.5 g/dl)  
 n = 1,006 n = 2,609  
Age (years) 72±10.7 67±11.1 <0.001 
Gender (% males) 47.5 74.7 <0.001 
BMI (kg/m2) 27.5±5.3 27.8±4.3 0.114 
Smokers (%) 21.2 31.8 <0.001 
LVEF (%) 56.3±12.5 57.8±12.1 0.001 
Concomitant diseases    
MI (%) 19.2 16.8 0.096 
COPD (%) 11.2 7.8 0.001 
Stroke (%) 6.3 4.6 0.051 
Hemofiltration (%) 5.3 0.4 <0.001 
PAOD (%) 9.7 6.6 0.002 
Hypertension (%) 80.9 78.8 0.183 
Diabetes (%) 34.6 22.9 <0.001 
Hyperlipidemia (%) 62.6 66.4 0.035 
Medications    
Diuretics (%) 57.8 36.7 <0.001 
ACE-Inhibitors (%) 47.6 45.2 0.192 
AT-blockers (%) 12.9 11.4 0.206 
Aspirin (%) 50.7 44.9 0.002 
Clopidogrel (%) 9.2 6.7 0.013 
Glucocorticoids(%) 4.0 2.9 0.114 
Biochemical parameters    
eGFR (ml/min/1.73 m2) 64.1±26.2 78.6±20.6 <0.001 
CRP (mg/dl) 2.3±4.7 0.7±1.6 <0.001 
25OHD (nmol/l) 46.9±30.4 49.3±26.0 0.026 
1,25(OH)2D (pmol/l) 46.7±26.8 60.6±27.5 <0.001 
Hemoglobin (g/dl) 11.1±1.1 14.3±1.1 <0.001 
Leukocytes (109/l) 8.2±3.8 7.8±3.1 0.003 
Erythrocytes (1012/l) 3.8±0.5 4.6±0.4 <0.001 
Hematocrit (%) 33.5±3.2 41.9±3.3 <0.001 
MCV (µm3) 89.3±6.3 90.4±4.5 <0.001 
MCH (pg Hb/red blood cell) 29.6±2.6 30.8±1.8 <0.001 
Thrombocytes (109/l) 249±100.8 231±72.7 <0.001 
  CHAPTER ONE 
 
24 
 
RDW (%) 14.0±2.2 12.4±1.2 <0.001 
ACE = Angiotensin-converting-enzyme; AT = Angiotensin receptor; BMI = Body Mass Index; COPD = chronic 
obstructive pulmonary disease; CRP = C-reactive protein; eGFR = estimated globular filtration rate; Hb = 
Hemoglobin; LVEF = Left ventricular ejection fraction; MCH = mean corpuscular/cellular hemoglobin; MCV = mean 
corpuscular/cell volume; MI = myocardial infarction; PAOD = peripheral artery occlusive disease; RDW = Red Blood 
Cell Distribution Width ([Sv x 100]/MCV) 
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Table 2:  Hematological parameters by cutoffs of 25-Hydroxyvitamin D 
25OHD <30 nmol/l 30-49.9 nmol/l 50-125 nmol/l >125 nmol/l P value 
 n = 945 n = 1281 n = 1328 n = 61 for trend 
Hemoglobin (g/dl) 13.0±2.0 13.5±1.8 13.5±1.7 12.8±1.8 <0.001 
Erythrocytes (1012/l) 4.3±0.6 4.4±0.6 4.4±0.6 4.2±0.5 <0.001 
Hematocrit (%) 38.7±5.4 39.8±5.0 39.9±4.6 38.2±4.8 <0.001 
MCV (μm3) 89.7±5.9 90.2±4.9 90.3±4.5 90.8±5.9 0.034 
MCH (pg 
Hb/Erythrocytes) 
30.2±2.5 30.6±2.0 30.6±1.8 30.4±2.5 <0.001 
Hb = Hemoglobin; MCH = mean corpuscular/cellular hemoglobin; MCV = mean corpuscular/cell volume 
 
Table 3:  Hematological parameters by cutoffs of 1,25-Dihydroxyvitamin D 
1,25(OH)2D <40 pmol/l 40-70 pmol/l >70 pmol/l P value 
 n = 1064 n = 1468 n = 1083 for trend 
Hemoglobin (g/dl) 12.7±1.9 13.5±1.7 13.9±1.6 <0.001 
Erythrocytes (1012/l) 4.2±0.6 4.4±0.6 4.6±0.5 <0.001 
Hematocrit (%) 37.6±5.3 39.9±4.8 40.8±4.3 <0.001 
MCV (μm3) 89.9±5.6 90.3±4.9 90.0±4.8 0.101 
MCH (pg Hb/Erythrocytes) 30.2±2.3 30.6±2.0 30.6±2.0 <0.001 
Hb = Hemoglobin; MCH = mean corpuscular/cellular hemoglobin; MCV = mean corpuscular/cell volume  
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Table 4:  Unadjusted and adjusted odds ratio (OR) for anemia by cutoffs of 25-Hydroxyvitamin D 
25OHD N Anemia (%) Model 1 Model 2 Model 3 Model 4 
nmol/l   OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) 
<30  945 337 (35.7) 1.79 (1.49-2.15) 1.63 (1.34-1.98) 1.50 (1.22-1.84) 1.48 (1.19-1.83) 
30-49.9  1281 331 (25.8) 1.13 (0.94-1.34) 1.06 (0.88-1.28) 1.06 (0.87-1.28) 1.05 (0.85-1.28) 
50-125  1328 314 (23.6) 1.0 (reference) 1.0 (reference) 1.0 (reference) 1.0 (reference) 
>125  61 24 (39.3) 2.10 (1.23-3.56) 2.27 (1.30-3.96) 1.69 (0.92-3.10) 1.34 (0.71-2.52) 
Model 1: unadjusted  
Model 2: adjusted for age, gender and season of blood drawing 
Model 3: adjusted as in model 2 and for concomitant diseases, medications, smoking, body mass index and left ventricular ejection fraction 
Model 4: adjusted as in model 3 and for kidney function (eGFR) and inflammatory process (CRP) 
 
Table 5:  Unadjusted and adjusted odds ratio (OR) for anemia by cutoffs of 1,25-Dihydroxyvitamin D 
1,25(OH)2D N Anemia (%) Model 1 Model 2 Model 3 Model 4 
pmol/l   OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) 
<40  1064 452 (42.5) 3.73 (3.05-4.56) 3.50 (2.83-4.33) 2.97 (2.38-3.71) 2.35 (1.86-2.97) 
40-70  1468 375 (25.5) 1.73 (1.42-2.11) 1.69 (1.37-2.08) 1.60 (1.29-1.98) 1.52 (1.22-1.89) 
>70  1083 179 (16.5) 1.0 (reference) 1.0 (reference) 1.0 (reference) 1.0 (reference) 
Model 1: unadjusted  
Model 2: adjusted for age, gender and season of blood drawing 
Model 3: adjusted as in model 2 and for concomitant diseases, medications, smoking, body mass index and left ventricular ejection fraction 
Model 4: adjusted as in model 3 and for kidney function (eGFR) and inflammation (CRP)
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Figure 1: Prevalence of deficient 25OHD levels according to subtypes of anemia. 
Figure legend: There were significant differences between subgroups (P<0.001). Number of 
patients in brackets. 
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Figure 2: Prevalence of 1,25(OH)2D levels <40 pmol/l according to subtypes of 
anemia. 
Figure legend: There were significant differences between subgroups (P<0.001). Number of 
patients in brackets. 
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Discussion 
This cross-sectional study demonstrates that low 25OHD and 1,25(OH)2D levels are 
independently associated with low Hb levels and anemia risk in patients scheduled for cardiac 
surgery. Patients with 25OHD values <30 nmol/l and 1,25(OH)2D values <40 pmol/l had the 
highest risk for anemia, whereas the risk was lowest in patients with adequate 25OHD levels 
(50-125 nmol/l) and 1,25(OH)2D levels above 70 pmol/l. Circulating 1,25(OH)2D was a better 
predictor of anemia than circulating 25OHD. 
Our data confirm earlier studies of an independent inverse association between circulating 
25OHD and anemia risk [5, 11, 12, 22, 25-30]. However, the association of 1,25(OH)2D with 
anemia risk has rarely been studied, and the few available studies on this topic have primarily 
been performed in patients with CKD and end-stage heart failure [13] [14]. In end-stage heart 
failure [14], Hb concentrations were 1.6 g/dL higher in patients with values >70 pmol/l 
compared to patients with values <40 pmol/l. These earlier findings are in general agreement 
with the data of the present study.  
There are several suggested causes why low 1,25(OH)2D may play a role in the development 
of anemia. Vitamin D modulates the level of systemic cytokine production. Therefore, vitamin 
D may reduce the inflammatory milieu that leads to anemia of chronic disease [11]. In addition, 
vitamin D may influence folate and iron absorption by increasing intestinal proton-coupled 
folate transporter [31] [32]. Iron participates in the renal activation of 25OHD into 1,25(OH)2D 
[33]; the enzymatic conversion is catalyzed by a cytochrome P450-dependent ferrodoxin 
reductase [34]. 1,25(OH)2D can also stimulate erythropoiesis in red blood cell precursor cells 
by increasing EPO sensitivity and can up-regulate proliferation of progenitor cells [17, 18]. First 
interventional studies support the hypothesis that 1,25(OH)2D administration and probably also 
high-dose bolus application of vitamin D is effective in enhancing Hb levels. Briefly, two studies 
in patients with CKD demonstrated an increase in mean Hb concentration after 12 months of 
intravenous 1,25(OH)2D administration by 1.0 mg/dL [15] and 1.2 mg/dL [16], and therefore 
improved control of anemia with reduced need for EPO. However, results must be considered 
preliminary since no control group was included in the two studies. In another study in 
hemodialysis patients, intravenous administration of 1,25(OH)2D decreased the weekly EPO 
dose requirement by 50% [35]. Similarly, high-dose monthly oral vitamin D2 administration 
(50,000 IU) was associated with non-significant [36] and significant [37] reductions in doses of 
erythropoiesis-stimulating agents (ESA), while mean Hb levels remained unchanged. 
Interestingly enough, it has been demonstrated that high-dose oral bolus administration of 
vitamin D is even able to increase circulating 1,25(OH)2D levels in CKD patients [38]. 
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Data obtained in the United States demonstrate that blood transfusion is the most common 
procedure performed during hospitalization (11.0% of hospital stays with a procedure) [39]. 
With a range of 35.8% to 60.0%, the transfusion rate in patients undergoing a cardiovascular 
procedure is very high [40-46]. However, the use of blood transfusion involves several risks. 
Blood transfusion is an independent risk factor for clinical complications like prolonged 
ventilatory support [3, 7], increased length of hospital stay [45, 46], infection [43-45, 47] and 
mortality [40-43, 45]. The increased risk of blood transfusion has been attributed to the 
presence of leucocytes in allogeneic blood transfusion thereby causing immunomodulatory 
events [48]. In addition, duration of blood storage influences clinical outcome with higher 
incidence of prolonged mechanical ventilation, renal failure, sepsis and in-hospital mortality in 
patients receiving older blood products (>14 days) [49]. Besides the use of leukocyte-depleted 
red blood cells and short storage time, reduction or even avoidance of the use of blood 
transfusion might be another interesting approach. Anemia is the most important risk factor for 
transfusion [50]. If confirmed in randomized controlled trials, administration of vitamin D or its 
active form 1,25(OH)2D could be a promising preventive or therapeutic option to decrease the 
prevalence of anemia in elective cardiac surgical patients. Of note, CKD patients (stages IV 
and V) should preferably be treated with activated vitamin D.  
In our study, prevalence of deficient 25OHD levels was highest in anemia of nutrient deficiency, 
whereas low 1,25(OH)2D levels were most frequent in anemia of CKD. With regard to CKD, 
this may be due to low GFR, resulting in reduced 1,25(OH)2D synthesis. However, it may also 
be that CKD-induced increased 24-hydroxylase activity [51] leads to enhanced conversion of 
25OHD and 1,25(OH)2D into their 24-hydroxylated inactive forms. It is well known that 
1,25(OH)2D levels are suppressed in CKD. However, low 1,25(OH)2D levels were also present 
in anemia of inflammation and anemia of nutrient deficiency. It has recently been shown that 
low 1,25(OH)2D levels are independently associated not only with poor kidney function but also 
with low 25OHD levels, high CRP levels, diabetes mellitus and high values of the cardio-
surgical risk marker EuroSCORE [19]. It may therefore well be that the anemia subtype 
‘nutrient deficiency’ may only be a surrogate for poor health status and that circulating 
1,25(OH)2D levels are also suppressed by other, currently unknown factors.  
Our study has some strengths but also some limitations. Its strengths are measurement of the 
active vitamin D hormone, 1,25(OH)2D, in a large cohort of patients and adjustments for several 
demographical and clinical variables. One inherent limitation is the observational study design, 
which prevents us from concluding that the association between 25OHD and 1,25(OH)2D 
deficiency and anemia is causal. It is another limitation that we were unable to assess the use 
of ESA or to measure EPO concentrations. However, since the association of low 1,25(OH)2D 
levels with anemia was highest in anemia of CKD, it is rather unlikely that ESA were frequently 
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used in our study cohort. Finally, no data on parathyroid hormone, magnesium or fibroblast 
growth factor 23 levels were available, parameters that are involved in 1,25(OH)2D regulation 
and therefore play a central role in vitamin D metabolism. 
In conclusion, our study demonstrates that 25OHD and 1,25(OH)2D levels are independently 
associated with low Hb concentrations and high anemia risk in cardiac surgical patients. 
Circulating 1,25(OH)2D was a better predictor of anemia than circulating 25OHD. Future 
studies have to clarify whether the association is causal and whether preoperative 
administration of vitamin D or 1,25(OH)2D is able to successfully prevent or treat anemia in 
patients scheduled for cardiac surgery. 
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Abstract 
Purpose: Anemia and vitamin D deficiency are both frequent in adult patients. Whether low 
vitamin D metabolite levels are an independent risk factor for different subtypes of anemia 
remains to be studied in detail.   
Methods: In 3,299 patients referred for coronary angiography, we investigated the association 
of 25-hydroxyvitamin D (25OHD) and 1,25-dihydroxyvitamin D (1,25[OH]2D) with anemia 
(hemoglobin [Hb] <12.5 g/dL) of specific subtypes.  
Results: Compared with patients with 25OHD levels in the adequate range (50-125 nmol/l), 
patients with deficient 25OHD concentrations (<30 nmol/l; 33.6% of patients) had 0.6 g/dL 
lower Hb levels. Hb values were 1.3 g/dL lower in patients with 1,25(OH)2D levels <40 pmol/l 
(5.4% of patients), compared with patients in the highest 1,25(OH)2D category (>70 pmol/l). Of 
the participants, 16.7% met the criteria for anemia. In multivariate-adjusted regression 
analyses, the odds ratios for anemia in the lowest 25OHD and 1,25(OH)2D categories were 
1.52 (95%CI:1.15-2.02) and 3.59 (95%CI:2.33-5.52), compared with patients with 25OHD 
levels in the adequate range and patients with 1,25(OH)2D levels >70 pmol/l. The probability 
of anemia was highest in patients with combined 25OHD and 1,25(OH)2D deficiency 
(multivariable-adjusted odds ratio 5.11 [95%CI:2.66-9.81]). Patients with anemia of chronic 
kidney disease had the highest prevalence of 25OHD deficiency and 1,25(OH)2D 
concentrations of <40 pmol/l.  
Conclusions: Low 25OHD and 1,25(OH)2D concentrations are independently associated with 
anemia. Patients with poor kidney function are most affected. Interventional trials with are 
warranted to prove whether administration of plain or activated vitamin D can prevent anemia. 
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Introduction 
With an estimated global prevalence rate of approximately 25% anemia is a common health 
problem [1]. In various medical conditions such as hemodialysis, heart failure, cardiac and non-
cardiac surgery, anemia is an independent risk factor for increased morbidity and mortality [2]. 
Low vitamin D status, e.g. 25-hydroxyvitamin D (25OHD) levels <50 nmol/l, is also frequently 
seen in elderly patients [3]. Recent observational studies have indicated an association 
between vitamin D status and anemia risk in community-dwelling older people [4,5], Asian 
children and adolescents [6] and different groups of patients [7-11]. There is however some 
evidence that the active vitamin D hormone 1,25-dihydroxyvitamin D (1,25[OH]2D) is a better 
predictor of anemia than circulating 25OHD [4,7,10]. In line with these data, first interventional 
studies in hemodialysis patients testing intravenous 1,25(OH)2D administration showed an 
increase in Hb levels, leading to improved control of anemia and reduced need for 
erythropoietin (EPO) [12,13]. 
According to experimental studies, vitamin D (i) can stimulate erythropoiesis in red cell 
precursor cells via increased EPO sensitivity [14], (ii) reduces pro-inflammatory cytokine 
production [11], (iii) enhances cellular folate uptake [15], and (iv) may increase intestinal iron 
absorption [16], whereas the enzymatic activation of 25OHD into 1,25(OH)2D may be 
suppressed by low iron availability [17].  
Since large studies on the association between vitamin D metabolites and specific subtypes 
of anemia are almost completely lacking, we aimed to examine in patients referred to coronary 
angiography the associations between the vitamin D metabolites 25OHD and 1,25(OH)2D with 
anemia (Hb <12.5 g/dL) of specific subtypes. 
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Methods 
Study Population 
The Ludwigshafen Risk and Cardiovascular Health Study (LURIC) is a prospective cohort 
study of 3,316 Caucasian patients referred to coronary angiography [18]. Patients were 
recruited between July 1997 and January 2000 at a single tertiary care center in southwestern 
Germany (Herzzentrum Ludwigshafen). Inclusion criteria were as follows: Caucasian origin, 
availability of a coronary angiogramm and clinical stability with the exception of acute coronary 
syndromes. Exclusion criteria were: any acute illness other than acute coronary syndromes, 
any chronic disease where non-cardiac disease predominated and a history of malignancy 
within the past five years. In 3,299 study participants, serum concentrations of 25OHD and 
1,25(OH)2D as well as hematological parameters were available. These patients were included 
in our analysis. The study was approved by the ethics committee at the ‘Ärztekammer 
Rheinland-Pfalz’ (Mainz, Germany). All participants gave their informed written consent.  
Data Assessment 
For data analysis, 25OHD, 1,25(OH)2D, parathyroid hormone (PTH), fibroblast growth factor 
23 (FGF-23), Hb, hematocrit, erythrocytes, mean corpuscular volume (MCV), mean 
corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentration (MCHC), iron, 
ferritin, transferrin, soluble transferrin receptor, folic acid, vitamin B12, C-reactive protein 
(CRP), hepcidin, creatinine and cystatin C were included. In addition, patient characteristics 
like age, sex, body mass index (BMI), smoking, concomitant diseases and medication use 
were considered.  
Biochemical Analysis 
Fasting venous blood samples were drawn in the morning, before coronary angiography was 
performed. Basic biochemical parameters were immediately measured as described [18]. One 
milliliter aliquots of serum were shock frozen in liquid nitrogen and stored at -80°C for later use. 
Serum concentrations of 25OHD and 1,25(OH)2D were determined using radioimmunoassays 
(DiaSorin Antony, France; Stillwater, MN, USA and Nichols Institute Diagnostika GmbH, Bad 
Nauheim, Germany, respectively). FGF-23 and hepcidin were measured by enzyme-linked 
immunosorbent assays (Immundiagnostik AG, Bensheim, Germany and DRG Instruments 
GmbH, Marburg, Germany, respectively). Hb was measured by cyanmethemoglobin method 
(Technicon H1, Technicon GmbH, Bad Vilbel, Germany; Advia 120 Bayer Diagnostics, 
Tarrytown, USA). Transferrin was determined by immunoturbidimetry, serum iron was 
determined by a colorimetric ferrozine assay on a Hitachi 717 analyzer, ferritin and PTH were 
analyzed by electrochemiluminescence immunoassay on an Elecsys 2010 Roche and 
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creatinine was determined by the method of Jaffé at 37°C with a Hitachi 717 autoanalyzer and 
commercial kits (Roche, Mannheim, Germany). CRP, cystatin C and soluble transferrin 
receptor were measured by immunonephelometry (N Latex CRP mono, Dade Behring, 
Marburg, Germany). Folic acid and vitamin B12 concentrations were analyzed using ion 
capture immunoassay and microparticle enzyme immunoassay, respectively (Abbott AXYM 
autosampler, Abbott Diagnostics, Wiesbaden, Germany). 
According to earlier classifications [8,10], Hb concentrations <12.5 g/dL were considered as 
anemic. This is the average threshold value of the World Health Organization´s gender based 
definition (<13 g/dL in men; <12 g/dL in women). We used earlier approaches to classify 
anemia hierarchically according to subtypes [5,8,10]: anemia of nutrient deficiency was present 
when subjects met one of these criteria: iron deficiency (≥ 2 of the following: serum ferritin <12 
ng/mL, transferrin saturation <15 % and MCV <80 μm3); folate deficiency (serum folate <2.6 
μg/L) or vitamin B12 deficiency (serum levels <200 ng/L); anemia of chronic kidney disease 
(CKD; eGFR <60 ml/min per 1.73 m2), anemia of inflammation (CRP >1 mg/dL or serum iron 
<60 μg/dL) and unexplained anemia if none of these subtypes were present. 
Estimated glomerular filtration rate (eGFR) was calculated using the following equation: GFR 
(mL/min/1.73 m2) = 177.6*[creatinine (mg/dL]-0.65*[cystatin C (mg/L)]-0.57*age-0.20*0.82 (if 
female) [19]. Transferrin saturation (%) was calculated using the following equation: (serum 
iron/5.5)/(transferrin/100)*3.98. 
Statistics 
Categorical variables are reported as percentage of observations and continuous variables as 
mean and standard deviation. We tested normal distribution of the data using the Kolmogorov-
Smirnov test. Normal distribution was considered if probability values were greater than 0.05. 
Clinical parameters were compared using Chi-squared test. Since several demographic and 
biochemical parameters were non-normally distributed, the non-parametric Mann-Whitney-U-
test and Kruskal-Wallis-test were used, when appropriate. According to the Institute of 
Medicine [20], 25OHD status was classified as follows: deficiency (<30 nmol/l), inadequacy 
(30-49.9 nmol/l), adequacy (50-125 nmol/l) and potentially harmful (>125 nmol/l). Based on 
earlier classifications [7,10], 1,25(OH)2D values were divided into three categories (<40 pmol/l; 
40-70 pmol/l; >70 pmol/l).  
To assess the independent association of 25OHD and 1,25(OH)2D categories with anemia, we 
performed logistic regression analyses (unadjusted and multivariable-adjusted). Results are 
expressed as odds ratios (ORs) with 95% confidence intervals (CI). We considered the groups 
with adequate 25OHD levels (50-125 nmol/l) and 1,25(OH)2D levels >70 pmol/l as a reference 
group. The following covariates were included in multivariable models: model 1: unadjusted 
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data; model 2: adjusted for age, gender and season of blood sampling (winter: January-March; 
spring: April-June; summer: July-September; fall: October-December); model 3: model 2 plus 
adjustments for BMI, smoking, concomitant diagnoses (coronary artery disease [CAD], history 
of stroke, diabetes mellitus, myocardial infarction [MI]) and medications (antibiotics, ACE-
inhibitors/AT-blockers, calcium-antagonists, glucocorticoids, statins, digitalis, diuretics); model 
4: model 3 plus adjustments for kidney function (eGFR in ml/min per 1.73 m2), inflammatory 
processes (CRP, hepcidin), iron status (ferritin, transferrin saturation) and nutritional status 
(folic acid, vitamin B12). Considering that there exists no universally accepted classification for 
1,25(OH)2D, we performed sensitivity analysis by using tertiles of 1,25(OH)2D (<70.5 pmol/l; 
70.5-97.75 pmol/l; >97.75 pmol/l) and considered the highest tertile as reference group. 
Interrelationships between variables were assed using Spearman’s rank correlation coefficient 
(rs). We considered P-values <0.05 as statistically significant. P-values are two-sided. 
Analyses were performed using SPSS version 21.0 (SPSS, Inc., Chicago, IL, USA). 
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Results 
Of the study cohort, 33.6% had deficient 25OHD levels (<30.0 nmol/l), 32.3% had inadequate 
25OHD levels (30.0-49.9 nmol/l), 33.7% had 25OHD levels in the adequate range (50-125 
nmol/l) and 0.4% had 25OHD levels above 125 nmol/l; 5.4% had 1,25(OH)2D <40 pmol/l, 
27.4% had 1,25(OH)2D between 40 and 70 pmol/l and 67.2% had concentrations above 70 
pmol/l. 25OHD and 1,25(OH)2D were inversely correlated with PTH levels (25OHD: 
rs= -0.25;P<0.001; 1,25(OH)2D: rs= -0.05;P=0.008).  
16.7% of participants met the criteria for anemia. In detail, 3.4% had anemia of nutritional 
deficiency (1.0% iron deficiency; 2.4% folate or vitamin B12 deficiency), 3.4% had anemia of 
CKD; 5.7% had anemia of inflammation, and 4.2% had unexplained anemia. In Table 1, 
baseline characteristics of the participants are presented, according to anemia status. Anemic 
participants were older, had a lower mean BMI, were more frequent women but less often 
smokers than non-anemic patients. While prevalence rates of arterial hypertension, peripheral 
vascular disease and history of venous thrombosis/pulmonary embolism did not differ between 
the two groups, anemic patients suffered significantly more often from all other concomitant 
diseases (CAD, history of stroke, diabetes mellitus, MI, cancer and acute infectious diseases). 
The intake of antibiotics, ACE-inhibitors/AT-blockers, calcium-antagonists, statins, digitalis and 
diuretics differed between anemic and non-anemic patients. Compared with non-anemic 
patients, circulating 25OHD and 1,25(OH)2D levels were significantly lower and PTH and FGF-
23 levels significantly higher in anemic patients. In addition, anemia was associated with 
reduced MCV, MCH and MCHC. 
Hb values were lowest in the groups with the lowest 25OHD and 1,25(OH)2D values. 
Compared with patients with adequate 25OHD (50-125 nmol/l) and 1,25(OH)2D levels >70 
pmol/l, Hb concentrations were 0.6 g/dL and 1.3 g/dL lower in patients with deficient 25OHD 
and 1,25(OH)2D <40 pmol/l, respectively (both P-values <0.001). Iron, ferritin, transferrin, 
transferrin saturation, folic acid, vitamin B12 and eGFR were significantly lower and CRP and 
cystatin C significantly higher in patients with deficient 25OHD and 1,25(OH)2D <40 pmol/l, 
compared with patients with adequate 25OHD and 1,25(OH)2D >70 pmol/l (Supplemental 
Tables 1 and 2). 
Table 2 presents the ORs for anemia across the categories of circulating 25OHD and 
1,25(OH)2D. Compared with the respective reference groups, in those patients who had lowest 
25OHD and 1,25(OH)2D, the ORs were 2.50 (95%CI:2.0-3.14) and 5.59 (95%CI:3.82-7.68) in 
the unadjusted models, respectively. In the fully adjusted models, the ORs for anemia in the 
lowest 25OHD and 1,25(OH)2D categories were 1.52 (95%CI:1.15-2.02) and 3.59 
(95%CI:2.33-5.52), respectively. In participants with combined 25OHD and 1,25(OH)2D 
  CHAPTER TWO 
 
44 
 
deficiency (n=115) the unadjusted and fully adjusted ORs for anemia were 8.13 (95%CI:5.30-
12.47) and 5.11 (95%CI:2.66-9.81), compared with the adequate 25OHD and highest 
1,25(OH)2D category, respectively. Patients with anemia of CKD had the highest prevalence 
of 25OHD deficiency and 1,25(OH)2D levels <40 pmol/l (Figures 1 and 2). Results did not 
change substantially if patients with an eGFR <60 ml/min per 1.73 m2 were excluded (data not 
shown). The ORs for anemia subtypes were for 25OHD (reference: non-anemic patients) as 
follows: anemia of nutrient deficiency: 2.99 (95%CI:2.04-4.38); anemia of CKD: 3.27 
(95%CI:2.23-4.79); anemia of inflammation: 2.16 (95%CI:1.61-2.91); unexplained anemia: 
1.84 (95%CI:1.30-2.60). The corresponding ORs were for 1,25(OH)2D (reference: non-anemic 
patients) as follows: anemia of nutrient deficiency: 5.35 (95%CI:3.14-9.11); anemia of CKD: 
13.27 (95%CI:8.57-20.57); anemia of inflammation: 2.26 (95%CI:129-3.97); unexplained 
anemia: 0.99 (95%CI:0.40-2.46). 
In sensitivity analysis, the fully adjusted OR for anemia in participants in the lowest 1,25(OH)2D 
tertile (<70.5 pmol/l) was 1.82 (95%CI:1.37-2.42), compared to those in the highest tertile 
(>97.75 pmol/l). The association of 25OHD with anemia did not change substantially, when 
25OHD levels were classified into tertiles (data not shown). 
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Table 1: Baseline Characteristics of the study cohort by anemia status 
 
Anemic  
(<12.5 g/dl) 
n = 552 
Non-anemic  
(≥12.5 g/dl) 
n = 2747 
P value 
n (%) 16.7 83.3  
Age (years) 67±9.9 62±10.5 <0.001 
Gender (% males) 42.0 75.2 <0.001 
BMI (kg/m2) 26.9±4.4 27.6±4.0 <0.001 
Smokers (%) 57.4 65.3 <0.001 
Concomitant diseases (%) 
CAD 
Stroke 
Arterial hypertension 
Diabetes 
Myocardial Infarction 
Peripheral vascular disease 
Cancer 
Venous thrombosis/pulmonary 
embolism 
Acute infectious disease 
 
84.2 
15.6 
62.0 
24.3 
48.6 
11.1 
12.2 
7.3 
 
 
13.1 
 
76.6 
7.8 
57.8 
16.1 
39.8 
9.2 
6.3 
5.8 
 
 
8.9 
 
<0.001 
<0.001 
  0.069 
<0.001 
<0.001 
  0.170 
<0.001 
  0.174 
 
 
  0.002 
Medication (%) 
Antibiotics 
ACE-Inhibitors/AT-Blockers 
Aspirin/other Antiplatelets 
Beta-Blockers 
Calcium-Antagonists 
Glucocorticoids 
Vitamin K-Antagonists 
Statins 
Digitalis 
Diuretics 
Vitamin Supplementations 
 
3.6 
65.4 
73.2 
65.2 
19.2 
2.7 
7.1 
52.5 
22.1 
38.9 
2.9 
 
1.3 
55.2 
71.1 
63.1 
15.0 
2.0 
6.6 
45.9 
14.1 
26.3 
2.4 
 
<0.001 
<0.001 
  0.329 
  0.343 
  0.013 
  0.260 
  0.706 
  0.004 
<0.001 
<0.001 
  0.461 
25OHD (nmol/l) 35.9±22.3 44.9±24.2 <0.001 
1,25(OH)2D (pmol/l) 73.7±34.3 90.5±34.4 <0.001 
PTH (ng/L) 39.0±43.0 33.0±24.3 <0.001 
FGF-23 (RU/mL) 312.0±2273.9 86.1±316.1 <0.001 
Hb (g/dL) 11.5±0.8 14.3±1.1 <0.001 
Hct (%) 34.4±2.6 41.8±3.2 <0.001 
Leukocytes (109/L) 7.0±2.4 7.1±2.1   0.027 
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Erythrocytes (1012/L) 3.9±0.4 4.7±0.4 <0.001 
MCV (μm3) 88.2±5.8 89.4±4.5 <0.001 
MCH (pg Hb/red blood cell) 29.6±2.3 30.6±1.7 <0.001 
MCHC (g/L) 33.6±1.3 34.2±1.1 <0.001 
Thrombocytes (109/L) 251.0±80.3 228.8±65.2 <0.001 
Iron (μg/dL) 67.1±32.0 97.9±38.3 <0.001 
Ferritin (ng/mL) 188.5±234.9 220.7±200.5 <0.001 
Transferrin (mg/dL) 243.0±48.0 253.3±28.3 <0.001 
Transferrin saturation (%) 20.6±10.9 28.5±11.9 <0.001 
sTfR (mg/L) 1.4±0.7 1.3±0.5   0.279 
Folic acid (μg/L) 8.0±3.0 8.2±2.8   0.071 
Vitamin B12 (ng/L) 417.3±274.5 391.0±212.0   0.911 
CRP (mg/dL) 2.0±3.2 0.8±1.5 <0.001 
Hepcidin (ng/mL) 9.0±10.9 8.1±6.5   0.584 
TNF-α (ng/L) 11.1±7.3 9.7±10.5 <0.001 
eGFR (mL/min/1.73 m2) 71.6±21.9 83.2±18.7 <0.001 
Cystatin C (mg/L) 1.2±0.7 1.0±0.3 <0.001 
Homoarginin (μmol/L) 2.0±0.9 2.7±1.1 <0.001 
ACE = angiotensin-converting-enzyme; AT = angiotensin receptor; BMI = body mass index; CRP = C-reactive 
protein; CAD = coronary artery disease; eGFR = estimated globular filtration rate; FGF-23 = fibroblast growth factor 
23; Hb = hemoglobin; MCH = mean corpuscular hemoglobin; MCHC = mean corpuscular hemoglobin concentration; 
MCV = mean corpuscular volume; PTH = parathyroid hormone; sTfR = soluble transferrin receptor; TNF-α = tumor 
necrosis factor-α 
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Table 2:  Unadjusted and adjusted odds ratio (OR) for anemia by cutoffs of 25-Hydroxyvitamin D and 1,25-Dihydroxyvitamin D 
Vitamin D N Anemia N (%) 
Model 1 
OR (95% CI) 
Model 2 
OR (95% CI) 
Model 3 
OR (95% CI) 
Model 4 
OR (95% CI) 
25OHD 
<30 nmol/l 
30-49.9 nmol/l 
50-125 nmol/l 
>125 nmol/l 
 
1107 
1067 
1111 
14 
 
281 (25.4) 
135 (12.7) 
133 (12.0) 
3 (21.4) 
 
2.50 (2.0-3.14) 
1.07 (0.83-1.38) 
1.0 (reference) 
2.0 (0.6-7.28) 
 
1.81 (1.42-2.32) 
1.0 (0.76-1.29) 
1.0 (reference) 
1.84 (0.48-7.0) 
 
1.56 (1.21-2.02) 
0.96 (0.73-1.26) 
1.0 (reference) 
2.1 (0.55-7.95) 
 
1.52 (1.15-2.02) 
1.02 (0.76-1.36) 
1.0 (reference) 
1.93 (0.46-8.17) 
1,25(OH)2D 
<40 pmol/l 
40-70 pmol/l 
>70 pmol/l 
 
178 
905 
2216 
 
77 (43.3) 
209 (23.1) 
266 (12.0) 
 
5.59 (4.05-7.72) 
2.20 (1.80-2.69) 
1.0 (reference) 
 
5.41 (3.82-7.68) 
1.88 (1.52-2.32) 
1.0 (reference) 
 
4.45 (3.09-6.40) 
1.69 (1.35-2.10) 
1.0 (reference) 
 
3.59 (2.33-5.52) 
1.68 (1.32-2.15) 
1.0 (reference) 
Model 1: unadjusted  
Model 2: adjusted for age, gender and season of blood drawing 
Model 3: adjusted as in model 2 and for concomitant diseases, medications, smoking and BMI  
Model 4: adjusted as in model 3 and for kidney function (eGFR), inflammatory process (CRP, hepcidin), iron status (ferritin, transferrin saturation) and nutritional status (folic acid, 
vitamin B12) 
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Figure 1: Prevalence of deficient 25OHD levels according to subtypes of anemia 
Differences between subgroups were statistically significant (**P<0.01; 
***P<0.001 vs. non-anemic participants).  
Number of participants in brackets. 
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Figure 2: Prevalence of 1,25(OH)2D levels <40 pmol/l according to subtypes of 
anemia 
Differences between subgroups were statistically significant (**P<0.01; 
***P<0.001 vs. non-anemic participants). 
Number of participants in brackets. 
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Discussion 
Our data demonstrate that in patients referred to coronary angiography, both, low 25OHD and 
1,25(OH)2D levels are independently associated with anemia. Of note, the association of 
anemia was stronger with low circulating 1,25(OH)2D levels than with deficient circulating 
25OHD levels, even if in sensitivity analysis 70.5 pmol/l instead of 40 pmol/l was used as cutoff 
for inadequate 1,25(OH)2D levels. 
Our findings are in line with recent studies demonstrating an independent association of 
anemia risk with low 25OHD and/or 1,25(OH)2D concentrations in community-dwelling older 
people [4,5], Asian children and adolescents [6], heart failure patients [7], cardiac surgical 
patients [8,10] and CKD patients [9,11]. However, in a recent cross-sectional study examining 
1,666 older men [4], only serum 1,25(OH)2D levels, but not 25OHD levels were significantly 
associated with Hb levels. With respect to 25OHD, these data are not in line with our results. 
The differences may to some extent be due to the smaller number of individuals studied by 
Hirani et al.[4], leading to reduced statistical power to obtain significant results. Nevertheless, 
both, our study and the study by Hirani et al.[4] support the assumption that 1,25(OH)2D is a 
more important predictor of anemia risk than 25OHD [7,10]. In line with this, first interventional 
studies in CKD patients demonstrated an increase in Hb concentrations during 12 months of 
intravenous 1,25(OH)2D administration that was paralleled by reduced EPO need [12]. 
However, these earlier studies included only small numbers of patients and no control group. 
In our study, patients with anemia of CKD had the highest prevalence of 25OHD deficiency 
and 1,25(OH)2D levels <40 pmol/l. It is well known that CKD is associated with low 1,25(OH)2D 
levels [21]. Moreover, EPO synthesis is suppressed and anemia is prevalent in CKD patients 
[22,23]. Whether 1,25(OH)2D directly affects renal EPO synthesis is unknown. However, there 
is evidence that in CKD patients 1,25(OH)2D can stimulate erythroid precursors proliferation 
[14], suggesting effects of 1,25(OH) 2D on the bone marrow. Similar to the high prevalence of 
low 1,25(OH)2D levels, the prevalence of low 25OHD levels is higher in CKD patients 
compared with the general population [24]. It has been speculated that in CKD patients low 
25OHD and low 1,25(OH)2D levels result from increased 24-hydroxylase activity [25], thereby 
increasing 25OHD and 1,25(OH)2D catabolism. In the bone marrow, levels of 1,25(OH)2D are 
several 100-fold higher compared with plasma [26]. Normalizing tissue 25OHD may be 
necessary for providing adequate amounts of substrate for local tissue production of 
1,25(OH)2D [11]. Therefore, low 25OHD concentrations in CKD may lead to insufficient 
substrate availability for the extrarenal 1α-hydroxylase-induced synthesis of 1,25(OH)2D in 
hematopoietic tissues. It is also noteworthy that in CKD patients 1,25(OH)2D administration 
can increase 25OHD uptake of peripheral cells [27] suggesting that adequate circulating 
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1,25(OH)2D levels are necessary for sufficient local 25OHD availability. Consequently, both 
vitamin D metabolites may synergistically improve erythropoiesis. 
Our data demonstrate that low 1,25(OH)2D levels are primarily but not exclusively associated 
with poor kidney function. Low 1,25(OH)2D were paralleled by elevated PTH and FGF-23 
levels, the latter parameter being well-known for its suppressive effect on 1,25(OH)2D 
synthesis [28]. Recent studies in cardiac surgical patients [29] indicate that circulating 
1,25(OH)2D levels are probably less homeostatically regulated than hitherto assumed. In that 
study, low 1,25(OH)2D levels were associated not only with poor kidney function but also with 
low 25OHD levels, diabetes mellitus as well as high CRP levels and high values of the cardio-
surgical risk marker EuroSCORE. In our study cohort, the prevalence of 1,25(OH)2D levels 
<40 pmol/l (5.4%) was much lower than the prevalence of deficient 25OHD levels (33.6%). In 
patients with CKD stages IV and V and in some other groups of patients such as end-stage 
heart failure patients, the prevalence of 1,25(OH)2D levels <40 pmol/l is much higher than in 
the present study [7,30], and this may at least in part also explain differences in the prevalence 
of anemia between these groups of patients. Altogether, results indicate that in clinical practice 
low levels of 25OHD and 1,25(OH)2D may often both contribute to anemia.  
Our study has some strengths and also some limitations. Strengths are (i) the large number of 
included patients (ii), the availability of data on 25OHD, 1,25(OH)2D levels and specific anemia 
subtypes, and (iii) the opportunity of performing multivariable-adjusted analyses including 
important confounders (age, gender, season of blood drawing, BMI, smoking, concomitant 
diseases, medications). One limitation is the cross-sectional study design, which precludes us 
from concluding that there is a causal relationship between vitamin D metabolites and anemia. 
Despite careful adjustments of our analyses, we can therefore not exclude that low 25OHD 
and 1,25(OH)2D are just simply a consequence of diseases or pathologic conditions that 
contribute to anemia. The study was restricted to Caucasians at intermediate to high 
cardiovascular risk and may thus not be generalizable for the overall population. In addition, 
we have no data on reticulocytes, EPO concentrations or use of erythropoiesis-stimulating 
agents. Moreover, the number of patients with 25OHD levels >125 nmol/l was rather small. 
Therefore, we cannot definitively rule out a U-shaped or inverse J-shaped association of 
circulating 25OHD levels with anemia. Consequently, high dose daily vitamin D supplements 
or bolus administration of vitamin D should be performed with caution and/or accompanied by 
25OHD measurements. Finally, no generally accepted cutoffs for classifying circulating 
1,25(OH)2D values do exist. Hence, the use of different cut-offs influences the prevalence of 
low/inadequate circulating 1,25(OH)2D levels substantially.  
In conclusion, our data of a large cohort of patients referred to coronary angiography indicate 
an independent association of low circulating 25OHD and 1,25(OH)2D concentrations with low 
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Hb levels and anemia. Patients with poor kidney function have the highest prevalence of low 
circulating 25OHD and 1,25(OH)2D concentrations. Randomized controlled trials in patients 
with deficient 25OHD levels and/or low 1,25(OH)2D levels using plain and/or activated vitamin 
D are warranted to clarify whether this association is causal. 
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Abstract 
Purpose: Epidemiological evidence suggests that circulating 25-hydroxyvitamin D (25OHD) 
levels are inversely associated with hemoglobin (Hb) levels and anemia risk. We evaluated 
whether vitamin D supplementation improves Hb levels and reduces anemia risk in 
hypertensive patients.  
Methods: Two hundred patients with 25OHD levels <75 nmol/l who attended the Styrian 
Vitamin D Hypertension Trial were included, of whom 188 completed the trial. Patients 
randomly received 2800 IU vitamin D3 daily or a matching placebo for eight weeks.  
Results: Initially, the prevalence of anemic status (Hb levels <12.5 g/dl) and deficient 25OHD 
levels (<30 nmol/l) was 6.5% and 7.5%, respectively. All anemic patients had 25OHD levels 
>50 nmol/l. The mean (95% confidence interval) vitamin D effect on Hb levels was 0.04 (-0.14 
to 0.22) g/dl (P=0.661). Moreover, vitamin D treatment did not influence anemic status 
significantly (P>0.999). Likewise, vitamin D had no significant effect on Hb levels in the 
subgroups of anemic patients or in patients with initial 25OHD levels <30 nmol/l.  
Conclusion: In conclusion, a daily vitamin D supplement of 2800 IU for eight weeks did not 
improve Hb levels or anemic status in hypertensive patients. Future trials should focus on 
anemic patients with deficient 25OHD levels (e.g. <30 nmol/l) (clinicaltrials.gov 
[NCT02136771]). 
  
  CHAPTER THREE 
 
58 
 
Introduction 
Anemia is a global health problem [1] and an independent risk factor for increased morbidity 
and mortality in various groups of patients, especially in patients with chronic diseases and in 
the elderly [2]. Low levels of 25-hydroxyvitamin D (25OHD) are also highly prevalent among 
these patients [3].  
Recent epidemiological evidence suggests that circulating 25OHD is inversely associated with 
hemoglobin (Hb) levels [4-15]. The risk of anemia is highest at deficient 25OHD levels (i.e. <30 
nmol/l) and lowest at 25OHD levels of 50 to 125 nmol/l [4,6,15]. 
In chronic kidney disease (CKD) patients, some non-randomized intervention studies could 
already show that intravenous administration of activated vitamin D (1,25-dihydroxyvitamin D3 
= 1,25(OH)2D3) is associated with an increase in Hb levels within 12 months of treatment and 
a reduced need for erythropoietin (EPO) [16,17]. Moreover, intravenous 1,25(OH)2D3 
administration was associated with a decreased weekly EPO dose of 50% [18]. Regarding Hb 
levels, similar results have been obtained in hemodialysis patients with oral alfacalcidol (1α-
vitamin D3) after 8 weeks [19] and also after 12 and 18 months of treatment [20]. In 
hemodialysis patients, high-dose oral vitamin D2 (50,000 IU monthly) was associated with 
dose-reductions in erythropoiesis-stimulating agents (ESA), while Hb concentrations remained 
unchanged [21,22]. In children with CKD stage 5 and 25OHD levels <75 nmol/l, 12 weeks of 
vitamin D2 treatment in conjunction with 1,25(OH)2D3 was associated with a significantly 
reduced dose of ESA required to treat the children [23]. In anemic patients with preserved 
kidney function, however, one single intramuscular bolus of 600,000 IU vitamin D3 did not 
influence Hb levels [24]. Nevertheless, it is noteworthy that in general populations the effect of 
high-dose bolus administration of vitamin D on clinical outcomes has been questioned [25].  
The purpose of the present study was to determine the effect of a daily vitamin D3 supplement 
on Hb levels in a group of hypertensive patients with preserved kidney function and inadequate 
25OHD levels. 
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Methods  
Study Design 
This is a secondary analysis of the Styrian Vitamin D Hypertension Trial of a post-specified 
endpoint. The study was a randomized, double-blind, placebo-controlled, single-center trial 
which took place at the outpatient clinic at the Division of Endocrinology and Metabolism, 
Medical University of Graz, Austria. Major study results have already been published 
elsewhere [26]. The study was registered at EudraCT (No. 2009-018125-70) and 
clinicaltrials.gov (NCT02136771). All study participants gave written informed consent. The 
study was approved by the Ethics Committee of the Medical University of Graz, Austria. 
Participants 
Two hundred study participants (106 men and 94 women) were recruited from the clinics of 
the Department of Cardiology and the Department of Internal Medicine, Division of 
Endocrinology and Metabolism, Medical University of Graz, Austria from June 2011 to August 
2014. Eligible study participants were adults aged 18 years or older with a serum 25OHD 
concentration below 75 nmol/l and arterial hypertension. Pregnant or lactating women were 
excluded and also patients with hypercalcemia (serum calcium >2.65 mmol/l), regular vitamin 
D intake >880 IU per day during the last four weeks before the study, estimated glomerular 
filtration rate (eGFR) <15 mL/min per 1.73 m2, drug intake as part of another clinical study, 
acute coronary syndrome or cerebrovascular event in the previous two weeks, 24-hour systolic 
BP >160 mm Hg or <120 mm Hg, 24-hour diastolic BP >100 mm Hg, change in hypertensive 
treatment (drugs or lifestyle) in the previous four weeks or planned changes in antihypertensive 
treatment during the study, any disease with an estimated life expectancy of <1 year, any 
clinically significant acute disease requiring drug treatment, and chemotherapy or radiation 
therapy. 
Intervention 
Eligible study participants were randomly allocated to receive 2800 IU (70 μg) cholecalciferol 
as seven oily drops per day (Oleovit D3, Fresenius Kabi Austria, Graz, Austria) or a matching 
placebo for eight weeks. The dose of 2,800 IU vitamin D per day was chosen because a rule 
of thumb suggests that vitamin D supplementation of 1,000 IU increases 25OHD levels by 
approximately 25 nmol/l [27]. Given that a commonly used normal range of 25OHD is 75 to 
150 nmol/l [28] we conclude that a supplementation of 2,800 IU daily may be sufficient to 
increase the 25OHD level of most study participants to target ranges without causing supra-
physiological 25OHD levels. One hundred patients were assigned to the intervention group 
and 100 patients to the control group. Randomization was performed by web-based software 
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(www.randomizer.at) with a permuted block randomization (block size of 10 and stratification 
according to sex). 
Endpoints 
The primary outcome measures were Hb levels and anemia. In accordance with earlier 
classifications [4,6,29], Hb concentrations <12.5 g/dL were considered as anemic, which 
corresponded to the average threshold value of the World Health Organization gender-based 
definition (<13.0 g/dL in men and <12.0 g/dL in women). 
Biochemical Measurements 
Blood sampling was performed in the morning between 7 and 11 am after an overnight fast. 
All blood samples were either measured at least four hours after blood collection or 
immediately stored at -20°C until analysis. Measurement of 25OHD was performed by 
chemiluminescence assay (IDS-iSYS 25-hydroxyvitamin D assay; Immunodiagnostic Systems 
Ltd., Boldon, UK) on an IDS-iSYS multidiscipline automated analyzer. Lower and upper 
quantification limits were 17.5 nmol/l and 312.5 nmol/l, respectively. All hematological 
parameters were measured on a Sysmex® XE-5000 automated hematology analyzer (Sysmex 
America, Inc., Mundelein, IL, USA). eGFR was calculated using the Modification of Diet in 
Renal Disease Formula [30]. The measurements of other biochemical parameters have been 
described elsewhere [26]. In accordance with published data [31,32] we categorized 25OHD 
levels < 30 nmol/l as deficient, 30-49.9 nmol/l as insufficient and 50 to 74.9 nmol/l as borderline. 
Statistics 
Categorical variables are reported as a percentage of observations. Normally distributed 
continuous data are shown as means with standard deviation. We used the Kolmogorov-
Smirnov test to check normal data distribution. Normal distribution was a consideration when 
probability values were >0.05. Variables with a skewed distribution are shown as medians with 
interquartile range. Change from baseline data are shown as means and 95% confidence 
interval (CI). We used the McNemar test and Fisher’s exact test, respectively, to assess 
differences in anemic status within and between groups. The unpaired t test or chi-squared 
test was used for group comparisons at baseline. Skewed variables were normalized by 
logarithmic transformation before use in parametric statistical analysis. ANCOVA with 
adjustments for baseline values was used to test for differences in the outcome variables 
between the vitamin D and the placebo group at the follow-up visit. We considered P-values 
<0.05 (two-sided) as statistically significant. Analyses were performed using SPSS version 
21.0 (SPSS, Inc., Chicago, IL, USA). 
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Results 
Baseline characteristics of the study participants are shown in Table 1. In both groups, mean 
Hb values were clearly above the anemia threshold of 12.5 g/dL. At baseline, the proportion of 
anemia in the vitamin D and placebo groups was 9.0% and 4.0%, respectively (P=0.152). 
Regarding 25OHD levels, 6.0% of the vitamin D group and 9.0% of the placebo group had 
deficient levels. The proportion of insufficient 25OHD levels was 27.0% and 36.0%, 
respectively. In the remaining 67.0% and 55.0%, the vitamin D status was classified as 
borderline.  
Of the 200 participants, 188 terminated the study as planned. Table 2 shows the treatment 
results on biochemical parameters. Circulating 25OHD increased on average by 35.4 nmo/l 
(95% CI: 31.2 to 39.6 nmol/l) in the treatment group and 8.1 nmol/l (95% CI: 4.6 to 11.7 nmol/l) 
in the placebo group (P<0.001). There was no significant vitamin D effect on Hb levels (Table 
2). In both study groups, Hb levels remained almost constant. Moreover, vitamin D treatment 
did not influence anemic status significantly (P>0.999). In detail, the percentage of anemic 
subjects remained constant in the vitamin D group (P>0.999) and increased only slightly in the 
placebo group (P>0.999) (Figure 1). Vitamin D treatment had no effect on other hematological 
parameters (Table 2).  
All anemic patients had initial 25OHD levels > 50 nmol/l. Vitamin D treatment had no effect on 
Hb levels and other hematological parameters in anemic patients (Table S1). Moreover, there 
was no vitamin D effect on Hb levels and other hematological parameters in the group of 
subjects with initial 25OHD levels <30 nmol/l (Table S2). 
There was, however, a significant vitamin D effect on PTH levels, with suppressed PTH levels 
in the vitamin D group (Table 2). Vitamin D treatment did not influence serum calcium and 
phosphate levels. 
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Table 1: Baseline characteristics of the study groups 
Characteristics Vitamin D Group 
(n = 100) 
Placebo Group 
(n = 100) 
P-Value 
Females (%) 46 48 0.777 
Age (years) 60.5±10.9 59.7±11.4 0.607 
Anemic subjects1 (%) 9 4 0.152 
BMI (kg/m2) 30.4±4.4 30.4±6.2 0.967 
Active smoker (%) 19 14 0.341 
Concomitant diseases (%)    
Previous MI  8 5 0.390 
Previous Stroke  9 7 0.602 
Diabetes Mellitus  32 41 0.186 
Biochemical parameters    
25OHD (nmol/l) 54.5±13.6 51.0±14.2 0.073 
PTH (pmol/l) 5.2 (4.2-6.5) 5.5 (4.2-7.0) 0.931 
Phosphate (mg/dL) 2.9±0.5 3.0±0.5 0.085 
Calcium (mmol/L) 2.37±0.10 2.37±0.11 0.989 
Hemoglobin (g/dL) 14.4±1.3 14.4±1.4 0.665 
Hematocrit (%) 41.1±3.3 41.5±3.4 0.329 
Leukocyte Counts (109/L) 5.9 (5.1-7.0) 6.0 (5.0-7.5) 0.817 
Erythrocyte Counts 
(1012/L) 
4.8±0.4 4.9±0.4 0.237 
MCV (µm3) 86.1±4.4 85.7±4.0 0.457 
MCH (pg Hb/red blood 
cell) 
30.1±1.9 29.8±1.6 0.234 
MCHC (g/L) 34.9±1.0 34.7±1.1 0.207 
Platelets (109/L) 239±64 232±50 0.442 
MPV (fl) 10.7±1.0 10.7±0.9 0.572 
CRP (mg/L) 2.3 (1.13-3.8) 1.4 (0.9-3.4) 0.044 
eGFR (ml/min/1.73 m2) 80.0±17.9 77.2±17.9 0.272 
Medications (%)    
Vitamin D supplement 5 9 0.268 
ACE-inhibitor 25 38 0.048 
AT II blocker 33 31 0.762 
Diuretic 42 48 0.394 
Beta-blocker 44 49 0.478 
Statin 26 32 0.350 
Calcium channel blocker 27 25 0.747 
1Hemoglobin <12.5 g/dL 
25OHD: 25-hydroxyvitamin D; ACE: angiotensin converting enzyme; AT: angiotensin; BMI: body mass index; 
CAD: coronary artery disease; CRP: C-reactive protein; eGFR: estimated globular filtration rate; MCV: mean 
corpuscular volume; MCH: mean corpuscular hemoglobin; MCHC: mean corpuscular hemoglobin concentration; 
MI: myocardial infarction; MPV: mean platelet volume; PTH: parathyroid hormone
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Table 2: Results of vitamin D treatment on hematological parameters, calcium and phosphate metabolism, and additional 
parameters in hypertensive subjects  
Characteristics Vitamin D group (n=93) Placebo group (n=95) Treatment Effect 
P-
value2 
 Baseline 
Follow-Up 
(8 weeks) 
Mean Change from 
Baseline1 
Baseline 
Follow-Up 
(8 weeks) 
Mean Change from 
Baseline1 
  
Hematological Parameters         
  Hemoglobin (g/dL) 14.4±1.3 14.3±1.3 -0.1 (-0.18 to 0.05) 14.4±1.4 14.3±1.3 -0.1 (-0.25 to 0.04) 0.04 (-0.14 to 0.22) 0.661 
  Hematokrit (%) 41.1±3.2 41.1±3.3 0.02 (-0.31 to 0.36) 41.5±3.5 41.3±3.2 -0.2 (-0.59 to 0.19) 0.16 (-0.33 to 0.65) 0.514 
  Erythrocytes (1012/L) 4.8±0.4 4.8±0.4 -0.02 (-0.05 to 0.02) 4.9±0.4 4.8±0.4 -0.04 (-0.09 to 0.00) 0.01 (-0.05 to 0.07) 0.691 
  MCV (µm3) 86.4±4.3 86.7±4.6 0.3 (-0.14 to 0.72) 85.6±4.0 86.0±4.0 0.3 (-0.09 to 0.77) 0.01 (-0.59 to 0.61) 0.971 
  MCH (pg Hb/RBC) 30.2±1.8 29.9±1.7 -0.04 (-0.16 to 0.08) 29.7±1.6 29.7±1.6 0.05 (-0.07 to 0.18) -0.08 (-0.25 to 0.09) 0.890 
  MCHC (g/L) 35.0±1.0 34.8±1.1 -0.2 (-0.3 to 0.00) 34.7±1.1 34.7±1.1 -0.09 (-0.3 to 0.09) -0.01 (-0.24 to 0.22) 0.938 
  Leucocytes (109/L) 5.9 (5.1-7.0) 6.0 (5.0-7.2) 0.04 (-0.18 to 0.26) 6.0 (5.0-7.5) 5.8 (5.0-6.9) -0.1 (-0.31 to 0.12) -0.13 (-0.17 to 0.42) 0.291 
  Platelets (109/L) 237±62 240±64 2.9 (-1.6 to 7.4) 231±50 232±53 1.7 (-3.8 to 7.1) 1.6 (-5.4 to 8.6) 0.651 
  Mean Platelet Volume (fl) 10.7±1.0 10.7±0.9 0.01 (-0.08 to 0.09) 10.8±0.9 10.8±0.9 -0.02 (-0.1 to 0.08) 0.01 (-0.12 to 0.13) 0.887 
Calcium and Phosphate 
Metabolism 
        
  25-Hydroxyvitamin D (nmol/l) 54.9±13.6 90.3±18.3 35.4 (31.2 to 39.6) 50.8±14.2 59.0±22.1 8.1 (4.6 to 11.7) 28.7 (23.5 to 34.2) <0.001 
  Parathyroid Hormone (pmol/l) 5.2 (4.3-6.5) 4.8 (4.0-5.8) -0.4 (-0.69 to -0.17) 5.4 (4.1-6.8) 5.3 (4.1-7.0) 0.18 (-0.13 to 0.49) -0.60 (-0.99 to -0.22) 0.003 
  Phosphate (mg/mL) 2.9±0.5 3.0±0.5 0.1 (0.02 to 0.22) 3.0±0.5 3.1±0.5 0.09 (-0.02 to 0.19) -0.01 (-0.14 to 0.11) 0.823 
  Calcium (mmol/l) 2.37±0.1 2.37±0.1 0.00 (-0.02 to 0.02) 2.37±0.1 2.35±0.1 -0.01 (-0.03 to 0.01) -0.01 (-0.03 to 0.01) 0.259 
Additional Parameters         
  C-Reactive Protein (mg/L) 2.1 (0.9-3.8) 2.2 (1.0-4.2) 0.3 (-0.6 to 1.2) 1.4 (0.8-3.0) 1.4 (0.6-4.1) 0.2 (-0.2 to 0.6) 0.15 (-0.69 to 1.2) 0.598 
  eGFR (mL/min/1.732) 80.5±18.1 77.9±18.8 -2.7 (-5.0 to -0.4) 77.5±17.6 76.7±16.9 -0.9 (-3.0 to 1.3) -1.3 (-4.3 to 1.7) 0.398 
1Change from Baseline data are shown as means and 95% confidence interval 
2ANCOVA with adjustments for baseline values was used to test for differences in the outcome variables between the vitamin D and the placebo group Abbreviations: MCV: mean 
corpuscular volume; MCH: mean corpuscular hemoglobin; Hb: hemoglobin; RBC: red blood cell; MCHC: mean corpuscular hemoglobin concentration; eGFR: estimated glomerular 
filtration rate 
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Figure 1: Anemia proportion in participants of the Styrian Vitamin D Hypertension 
Trial at baseline and study termination (by study group). P-values indicate 
within study group results. 
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Table S1: Effect of vitamin D treatment on hematological parameters in anemic hypertensive subjects 
Characteristics Vitamin D group (n=7) Placebo group (n=4) Treatment Effect P-value 
 Baseline 
Follow-Up 
(8 weeks) 
Mean change from 
Baseline 
Baseline 
Follow-Up 
(8 weeks) 
Mean change from 
Baseline 
  
Hematological Parameters         
Hemoglobin (g/dL) 11.8±0.7 11.8±0.9 -0.01 (-0.64 to 0.61) 10.8±1.3 10.9±1.0 0.15 (-1.74 to 2.04) 0.29 (-1.10 to 1.67) 0.643 
Hematokrit (%) 34.5±3.0 34.3±3.3 -0.10 (-1.59 to 1.34) 31.6±3.2 32.4±2.0 0.83 (-3.46 to 5.11) -0.15 (-3.35 to 3.06) 0.919 
Erythrocytes (1012/L) 3.89±0.6 3.91±0.7 0.01 (-0.19 to 0.21) 4.02±0.3 4.04±0.3 0.23 (-0.46 to 0.51) 0.00 (-0.38 to 0.38) 0.985 
MCV (μm3) 89.6±9.0 89.7±11.9 0.13 (-2.85 to 3.10) 78.5±5.0 80.3±3.9 1.75 (-1.75 to 5.20) -4.14 (-8.50 to 0.23) 0.060 
MCH (pg Hb/RBC) 28.8±1.2 28.5±1.3 -0.30 (-0.77 to 0.17) 26.8±2.4 27.0±2.1 0.28 (-1.35 to 1.90) -0.28 (-1.93 to 1.37) 0.677 
MCHC (g/L) 34.3±1.5 34.4±1.2 0.06 (-0.54 to 0.65) 34.0±1.5 33.6±1.3 -0.42 (-3.33 to 2.50) 0.62 (-0.81 to 2.06) 0.345 
 
Table S2: Effect of vitamin D treatment on hematological parameters in hypertensive subjects with initial 25OHD levels 
<30 nmol/l 
Characteristics Vitamin D group (n=6) Placebo group (n=8) Treatment Effect P-value 
 Baseline 
Follow-Up 
(8 weeks) 
Mean change from 
Baseline 
Baseline 
Follow-Up 
(8 weeks) 
Mean change from 
Baseline 
  
Hematological Parameters         
Hemoglobin (g/dL) 14.7±1.3 14.4±1.1 -0.28 (-0.82 to 0.26) 15.0±1.2 14.5±1.3 -0.46 (-0.80 to 0.11) 0.16 (-0.39 to 0.71) 0.543 
Hematokrit (%) 41.7±3.4 40.6±2.7 -1.15 (-2.55 to 0.25) 43.3±2.9 41.7±3.1 -1.52 (-2.67 to 0.37) 0.15 (-1.49 to 1.80) 0.841 
Erythrocytes (1012/L) 4.76±0.3 4.63±0.2 -0.12 (-0.23 to 0.02) 5.04±0.5 4.84±0.4 -0.19 (-0.30 to 0.07) -0.02 (-012 to 0.16) 0.750 
MCV (μm3) 87.6±4.4 87.4±4.2 -0.11 (-1.42 to 1.19) 86.0±4.8 86.1±4.8 0.11 (-2.02 to 2.25) -0.05 (-2.62 to 2.53) 0.969 
MCH (pg Hb/RBC) 30.9±2.2 31.0±2.2 0.18 (-0.56 to 0.92) 29.2±1.7 29.2±1.9 0.08 (-0.26 to 0.42) 0.06 (-0.70 to 0.81) 0.869 
MCHC (g/L) 35.1±0.9 35.4±0.6 0.28 (-0.31 to 0.88) 34.4±1.2 34.66±1.1 0.14 (-0.77 to 1.04) 0.48 (-0.49 to 1.46) 0.299 
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Discussion 
This study showed that a daily vitamin D supplement of 2800 IU for 8 weeks had no effect on 
Hb levels or anemia risk in hypertensive patients with 25OHD levels <75 nmol/l. 
Our study has several strengths. First, this is a randomized, placebo-controlled trial. In addition, 
compared with previous interventional studies we were able to include a large number of 
patients. Next, we included only patients with relatively low circulating 25OHD levels. 
Moreover, the daily vitamin D dose was sufficient to increase in-study 25OHD levels on 
average clearly above 75 nmol/l. This value is recommended by many endocrinologists and 
vitamin D researchers as the lower target level for various clinical outcomes [33,34]. Our study 
also has some limitations. First, the prevalence of anemic patients at baseline was low. 
Second, the study duration of 8 weeks was relatively short, given that the half-life of red blood 
cells in circulation is 3 months. Third, we have no data on circulating levels of 1,25(OH)2D, 
which is the active, hormonal form of vitamin D. 
Generally, evidence is increasing that 1,25(OH)2D can stimulate erythropoiesis in red blood 
cell precursor cells by increasing EPO sensitivity. Furthermore, 1,25(OH)2D can up-regulate 
proliferation of hematopoietic progenitor cells [35,36]. Nevertheless, our findings with plain 
vitamin D in patients with preserved kidney function do not support the beneficial impact on Hb 
levels of earlier studies with activated vitamin D in CKD patients [16,17]. It is, however, 
noteworthy that in CKD patients the prevalence of anemia is high and circulating 1,25(OH)2D 
levels are low. Moreover, a recent meta-analysis of randomized controlled trials has 
demonstrated that after administration of vitamin D or activated vitamin D, the increase in 
circulating 1,25(OH)2D tends to be much higher in CKD patients than in non-CKD patients [37]. 
In our study, a vitamin D-induced increase in circulating 1,25(OH)2D levels may have been 
blunted by the suppressed PTH levels, and this may have contributed - at least in part - to the 
null effect on Hb levels. 
In the present study, the prevalence of deficient 25OHD levels was low. Moreover, it was a 
surprising finding that all 13 anemic patients had initial 25OHD levels >50 nmol/l. Generally, 
epidemiological evidence suggests that circulating 25OHD levels are inversely associated with 
Hb levels and anemia risk [4,6]. A recent meta-analysis of retrospective observational studies 
showed that, compared with individuals with adequate 25OHD levels, low 25OHD levels were 
associated with an odds ratio for anemia of 2.25 (95% CI: 1.47-3.44) [38]. The cut-off for low 
25OHD levels was 50 nmol/l in 5 out of the 7 included studies and 75 nmol/l in the remaining 
2 studies. Only individuals without chronic diseases were included in that meta-analysis. 
However, two large studies in patients with cardiovascular disease [4,6] indicate that Hb levels 
are only significantly affected if circulating 25OHD levels are in the deficiency range. Also of 
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note is that observational studies have shown circulating 1,25(OH)2D to be a better predictor 
of anemia than circulating 25OHD [4,5,39]. Altogether, data indicate that especially anemic 
patients with deficient 25OHD levels and low circulating 1,25(OH)2D levels may benefit from 
improved vitamin D status. 
In conclusion, our data demonstrate that a daily vitamin D supplement of 2800 IU for 8 weeks 
does not increase Hb levels in non-anemic hypertensive patients with 25OHD levels <75 
nmol/l. Future studies in this field should focus on anemic individuals with deficient 25OHD 
levels. 
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Abstract 
Background and Aims: Low 25-Hydroxyvitamin D (25OHD) levels and anemia are both 
prevalent in heart failure (HF). We aimed to investigate whether vitamin D supplementation 
can reduce anemia risk by improving hemoglobin (Hb) levels in end-stage HF. 
Methods: EVITA (Effect of Vitamin D on Mortality in Heart Failure) was a randomized, placebo-
controlled clinical trial in patients with initial 25OHD levels <75 nmol/l. Participants received 
either 4,000 IU vitamin D3 daily or a matching placebo for 36 months. The present investigation 
was a post-hoc analysis in the per-protocol population (vitamin D group: n=85; placebo group: 
n=87) that used an analysis of covariance, while adjusting for baseline differences. 
Results: Of the study cohort, 11.6% were anemic (Hb <12.5 g/dL) and 42.4% had deficient 
25OHD levels (<30 nmol/l). Until study termination, anemia status increased by 12.9% in the 
vitamin D group and 10.3% in the placebo group, changes that were not influenced by vitamin 
D treatment (P=0.720). Moreover, there was no treatment effect on Hb levels (-0.04 g/dl [95% 
CI: -0.53 to 0.45 g/dL]; P=0.865). Results were unaffected by kidney function. Vitamin D 
treatment was however associated with a decrease in mean corpuscular hemoglobin 
concentration (-0.7 g/L [95%CI: -1.2 to -0.3 g/L]; P<0.001) and an increase in mean platelet 
volume (0.5 fL [95%CI: 0.2 to 0.9 fL]; P=0.007]) and plateletcrit (0.010% [95%CI: 0.00 to 
0.020%]; P=0.046). 
Conclusion: Our data indicate that a daily vitamin D supplement of 4,000 IU cannot be 
recommended for improving Hb levels or anemia risk in end-stage HF. 
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Introduction 
Both, anemia (Hemoglobin [Hb] <12.5 g/dL) and vitamin D deficiency (25-hydroxyvitamin D 
[25OHD] values <30 nmol/l) are prevalent in patients with heart failure (HF) [1-3]. The 
estimated prevalence of anemia in HF varies from 12% to 67% [4,5]. This wide range is, at 
least in part, due to the use of inconsistent definitions of anemia and the selection of different 
cohorts (e.g. new-onset HF, end-stage HF) [6]. The prevalence of 25OHD levels <25 nmol/l 
varies between 28% and 66.7% [7,8]. Compared with age-matched healthy controls, patients 
with HF also have lower concentrations of the active vitamin D hormone 1,25-dihydroxyvitamin 
D (1,25[OH]2D) [9]. 
Epidemiological evidence suggests that both aforementioned vitamin D metabolites are 
inversely associated with Hb levels and anemia risk in patients with cardiovascular disease 
[10-12]. including patients with HF [2]. There is also evidence from observational studies that 
the risk of anemia is stronger associated with low circulating 1,25(OH)2D levels than with 
deficient circulating 25OHD levels [2,11-13]. Nevertheless, results of interventional studies with 
vitamin D have been inconsistent: Early interventional studies with small numbers of patients 
and/or no control-group [14-17] support the assumption of beneficial vitamin D effects on 
erythropoiesis and anemia control. However, results of more recent randomized controlled 
trials (RCTs) are mixed [18-21]. While two studies showed no effect of vitamin D on anemia 
control [19,20] two other studies showed significant decreases in the required dose of 
erythropoietin (EPO) and erythropoiesis stimulating agents (ESA) in the vitamin D group, 
respectively [18,21]. 
In HF, anemia is an independent risk factor of morbidity [22] and mortality [23]. Treatment of 
anemia can improve patient outcome [24]. Therefore, the present study aimed at investigating 
the effect of a daily vitamin D3 supplement on Hb levels and anemia risk in patients with end-
stage HF and 25OHD levels <75 nmol/l.  
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Methods 
Study Design and Participants  
The present investigation is a secondary analysis of the EVITA (Effect of Vitamin D on Mortality 
in Heart Failure) trial. This study is a single-center, randomized, placebo-controlled, clinical 
trial, performed at the Clinic for Thoracic and Cardiovascular Surgery of the Heart- and 
Diabetes Center North Rhine Westphalia, Bad Oeynhausen, Germany. Main study results 
have already been published elsewhere. Briefly, between November 2010 and July 2013, 400 
patients with HF (332 men and 68 women) were recruited. All patients were ambulatory and 
regularly seen at our outpatient clinic. Eligible study participants were adults aged ≥18 to 79 
years with congestive HF and New York Heart Association functional class ≥II. Participants 
were randomly allocated to receive 4,000 IU (100 µg) cholecalciferol per day as oily drops 
(Vigantol® Oel, producer: Merck KGaA, Darmstadt, Germany) or a matching placebo (Miglyol 
Oel, producer: Merck KGaA, Darmstadt, Germany) for 36 months. During the study, 
participants remained on guideline-recommended medications. None of the study participants 
received erythropoietin (EPO). Out of the 400 patients, 177 completed the study as planned 
(Figure 1). In 172 patients, data on relevant parameters for this secondary analysis were 
available. The study was registered at EudraCT (number 2010-020793-42) and 
clinicaltrials.gov (NCT01326650). All study participants gave written informed consent. The 
study was approved by the Ethics Committee of the Medical Council of Westfalen-Lippe, 
Germany. 
Endpoints 
The primary outcome measures of the present investigation were change of the hematological 
parameter Hb and anemia risk. In line with earlier classifications [12,25-27]. Hb concentrations 
<12.5 g/dL were considered as anemic, which corresponds to the average threshold value of 
the World Health Organization’s gender-based definition (<13 g/dL in men and <12.0 g/dL in 
women). 
Biochemical Measurements 
Fasting venous blood samples were collected on study visits between 8 and 11 AM under 
standardized conditions. Blood samples were either measured directly within four hours of 
blood collection or stored at -80°C until analysis. Circulating 25OHD (sum of 25[OH]D2 and 
25[OH]D3) and 1,25(OH)2D (sum of 1,25[OH]2D2 and 1,25[OH]2D3) levels were measured by 
the autoanalyzer Liaison (DiaSorin, Stillwater, MN, USA). The measuring range for 25OHD lies 
between 10 and 375 nmol/l. Values <10 nmol/l were considered 9.9 nmol/l. The limit of 
1,25(OH)2D quantitation is 12 pmol/l, and we considered values below this limit as 11 pmol/l. 
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C-reactive protein (CRP) and creatinine values were analyzed by the Architect Autoanalyzer 
(Abbott, Wiesbaden, Germany). Estimated glomerular filtration rate (eGFR) was calculated 
using the Modification of Diet in Renal Disease [28]. Blood Hb, hematocrit (Htc), erythrocytes, 
leukocytes, thrombocytes, mean corpuscular volume (MCV), mean corpuscular hemoglobin 
(MCH), mean corpuscular hemoglobin concentration (MCHC), red blood cell distribution width 
(RDW), mean platelet volume (MPV), and plateletcrit were measured by automated 
procedures using the Abbott CellDyn 3500 hematology analyzer (Abbott, Wiesbaden, 
Germany). 
According to previous classification [25], we used the following cut-off values for classifying 
25OHD: <30 nmol/l as deficient, 30-49.9 nmol/l as insufficient, and 50-74.9 as borderline. 
Statistics 
Categorical data are presented as percentages. Continuous data with a normal distribution are 
shown as means with standard deviation (SD) and data with a skewed distribution are shown 
as medians with interquartile range. Normal data distribution was checked by using the 
Kolmogorov-Smirnov test and was considered when probability values were >0.05. We used 
the chi-squared test, unpaired t-test or Mann-Whitney-U-Test or for baseline study group 
comparisons.  
Change from baseline data is shown as mean with 95% confidence interval [CI]. Skewed 
variables were log(e) transformed before use in parametric statistical analyses. We used 
ANCOVA with baseline adjustments to test for differences in the outcome variables between 
the two study groups at follow-up (36 months). The McNemar test was used to assess 
differences in anemic status within groups. The Fisher´s exact test was used to assess 
differences in anemic status between groups. We considered P-values <0.05 as statistically 
significant. P-values are two-sided. Analyses were performed using SPSS version 21.0 (SPSS, 
Inc., Chicago, IL, USA). 
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Results 
Baseline characteristics of the participants are shown in Table 1. Initial MCV was significantly 
lower in the vitamin D group than in the placebo group. Compared with placebo, slightly but 
significantly more patients in the vitamin D group suffered from coronary heart disease. No 
significant group differences in any other clinical, biochemical, or medical treatment parameter 
was present (Table 1). At baseline, 11.8% and 11.5% in the vitamin D group and placebo 
group, respectively, were anemic. Moreover, 47.1% and 37.9% in the vitamin D group and 
placebo group, respectively, had deficient 25OHD levels. In addition, 30.6% and 22.4% in the 
vitamin D group and 41.4% and 20.7% in the placebo group had insufficient and borderline 
25OHD levels, respectively.  
Table 2 shows the results of vitamin D treatment on biochemical parameters. There was a 
significant treatment effect on circulating 25OHD levels. The increment was 55.3 nmo/l (95% 
CI: 43.5 to 67.1 nmol/l; P<0.001). The corresponding values concerning the effect on 
circulating 1,25(OH)2D were +17.1 pmol/l (95% CI: 6.2 to 27.9 pmol/l; P=0.004). There was 
however no significant treatment effect on Hb levels. In detail, in-study Hb levels decreased 
on average by -0.5 g/dL (95% CI: -0.9 to -0.2) g/dL and -0.5 g/dL (95% CI: -0.9 to -0.1) g/dL, 
in the vitamin D and placebo group, respectively. The mean treatment effect was -0.04 g/dL 
(95% CI: -0.53 to 0.45 g/dL; P=0.865). Anemia status increased by 12.9% in the vitamin D 
group (P=0.007) and 10.3% in the placebo group (P=0.049; Figure 2A). No difference in 
anemic status was determined between the two study groups at study termination (P=0.720; 
Figure 2B). Compared with placebo, there was a significant increase in MPV and plateletcrit 
and a significant decrease in MCHC in the vitamin D group (Table 2). However, mean values 
were still within the respective reference range for adults (reference ranges: MPV 7.4-10.4 fl; 
plateletcrit 0.162-0.346 %; MCHC 31-37 g/dL). In the subgroup of patients with chronic kidney 
disease (CKD) stage 3 or 4 (n=49), 18.4% and 34.7% were anemic at baseline and study 
termination, respectively. Again, no difference in anemic status was determined between the 
two study groups at study termination (vitamin D group: 38.5% vs. placebo group: 30.4%; 
P=0.764). Moreover, vitamin D had no effect on Hb levels (±0.0 g/dL [95% CI: -1.0 to 1.0 g/dL]; 
Supplemental Table 1). 
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Table 1: Baseline characteristics of the study groups 
Characteristics 
Vitamin D 100 µg 
(n=85) 
Placebo 
(n=87) 
P-Value 
Females (%) 12.9 21.8 0.124 
Age (years) 56 (49-61) 54 (47-59) 0.088 
Anemic subjects1 (%) 11.8 11.5 0.956 
BMI (kg/m2) 28.4 (25.0-31.4) 28.1 (25.7-32.2) 0.593 
NYHA (%)    
Class II 77.6 71.3 0.337 
Class III 22.4 28.7 0.337 
LVEF (%) 30.0 (23.5-35.0) 28.0 (24.0-35.0) 0.960 
LVED (mm) 66.0 (59.0-73.0) 66.0 (60.0-75.0) 0.973 
Primary Disease (%)    
Dilated cardiomyopathy 38.8 50.6 0.121 
Coronary heart disease 57.6 42.5 0.047 
Others 3.5 6.9 0.321 
Comorbidities (%)    
Diabetes 28.2 16.1 0.055 
Arterial hypertension 25.9 29.9 0.558 
Renal insufficiency 10.6 8.0 0.566 
Drug therapy (%)    
Loop diuretic 82.4 86.2 0.487 
Thiazide diuretic 25.9 31.0 0.454 
Aldosterone antagonist 81.2 86.2 0.372 
ACE- inhibitor 72.9 71.3 0.806 
AT II blocker 29.4 36.8 0.305 
Beta-blocker 96.5 97.7 0.631 
Digitalis 31.8 40.2 0.248 
Antiarrhythmic drug 24.7 28.7 0.551 
Lipid-lowering drug 57.6 54.0 0.632 
Calcium channel blocker 3.5 3.4 0.977 
Vitamin D supplement 0.0 0.0 >0.999 
Vitamin D metabolites    
25OHD (nmol/l) 30.7 (22.0-46.6) 34.4 (26.7-45.9) 0.374 
1,25(OH)2D (pmol/l)2 81.6 (60.8-100.9) 87.7 (65.2-104.8) 0.183 
Hematological parameters    
Hemoglobin (g/dL) 14.2±1.6 14.2±1.5 0.966 
Hematocrit (%) 42.2±4.9 42.2±4.2 0.932 
Leukocytes (109/L) 8.1 (6.8-9.6) 7.7 (6.2-9.6) 0.369 
Erythrocytes (1012/L) 4.7 (4.4-5.0) 4.6 (4.3-4.9) 0.415 
MCV (µm3) 90.6 (88.1-93.4) 92.9 (90.1-95.6) 0.005 
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MCH (pg Hb/red blood cell) 30.7±2.0 31.2±2.5 0.101 
MCHC (g/L) 33.6 (33.0-34.8) 33.9 (33.0-34.7) 0.870 
Thrombocytes (109/L) 211 (185-255) 212 (190-249) 0.932 
RDW (%) 12.7 (11.9-13.5) 12.5 (11.9-13.2) 0.319 
MPV (fl) 8.5 (7.5-9.3) 8.0 (7.3-9.3) 0.296 
Plateletcrit (%) 
0.183 (0.155-0.218) 
0.184 (0.153-
0.210) 
0.473 
Additional parameters    
eGFR (mL/min/1.73 m2) 71.7±22.5 75.8±23.4 0.237 
CRP (mg/dL)3 0.24 (0.10-0.69) 0.21 (0.09-0.40) 0.406 
1Hemoglobin <12.5 g/dL  
2data are based on 161 patients 
3data are based on 155 patients 
COPD: chronic obstructive pulmonary disease; CRP: C-reactive protein; eGFR: estimated globular filtration rate; 
LVEF; left ventricular ejection fraction; LVED: left ventricular end-diastolic diameter; MPV: mean platelet volume; 
RDW: erythrocytes distribution width 
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Table 2:  Results of vitamin D treatment on biochemical parameters in patients with chronic heart failure 
 
Vitamin D group (n=85) Placebo group (n=87) 
  
Characteristics Baseline Follow-up (36 
months) 
Mean change from 
baseline1 
Baseline Follow-up (36 
months) 
Mean change 
from baseline1 
Treatment effect P-value 
Vitamin D metabolites         
25OHD (nmol/l) 30.7 (22.0-46.6) 92.1 (65.6-128.0) 65.6 (55.0 to 76.3) 34.4 (26.7-45.9) 40.2 (30.5-57.9) 9.9 (4.3 to 15.5) 55.3 (43.5 to 67.1) <0.001 
1,25(OH)2D (pmol/l) 81.6 (60.8-100.9) 90.0 (68.3-121.8) 12.3 (3.1 to 21.4) 87.7 (65.2-104.8) 76.1 (60.5-105.1) -7.8 (-15.5 to 0.0) 17.1 (6.2 to 27.9) 0.004 
Hematological parameters         
Hemoglobin (g/dL) 14.2±1.6 13.7±1.8 -0.5 (-0.9 to -0.2) 14.2±1.5 13.8±1.9 -0.5 (-0.9 to -0.1) -0.04 (-0.53 to 0.45) 0.865 
Hematocrit (%) 42.2±4.9 41.6±5.7 -0.6 (-1.7 to 0.4) 42.2±4.2 40.9±5.6 -1.3 (-2.5 to -0.1) 0.7 (-0.8 to 2.2) 0.358 
Leukocytes (109/L) 8.1 (6.8-9.6) 8.2 (6.4-9.4) -0.3 (-0.7 to 0.1) 7.7 (6.2-9.6) 7.2 (5.7-9.2) -0.3 (-0.8 to 0.2) 0.2 (-0.4 to 0.7) 0.596 
Erythrocytes (1012/L) 4.7 (4.4-5.0) 4.7 (4.3-5.1) 0.0 (-0.1 to 0.1) 4.6 (4.3-4.9) 4.6 (4.1-5.0) -0.5 (-1.5 to 0.5) 0.15 (-0.04 to 0.33) 0.103 
MCV (µm3) 90.6 (88.1-93.4) 88.7 (84.8-94.0) -1.6 (-3.0 to -0.2) 92.9 (90.1-95.6) 90.6 (87.1-93.1) -1.9 (-3.6 to 0.1) 0.5 (-2.4 to 1.4) 0.329 
MCH (pg Hb/red blood cell) 30.7±2.0 29.4±2.7 -1.3 (-1.7 to 0.8) 31.2±2.5 30.3±2.2 -0.9 (-1.4 to 0.4) 0.6 (-1.3 to 0.0) 0.051 
MCHC (g/L) 33.6 (33.0-34.8) 32.9 (31.9-34.9) -0.8 (-1.2 to -0.4) 33.9 (33.0-34.7) 33.7 (32.8-34.5) -0.0 (-0.4 to 0.4) -0.7 (-1.2 to -0.3) 0.001 
Thrombocytes (109/L) 211 (185-255) 201 (168-242) -13 (-23 to -3) 212 (190-249) 210 (176-243) -12 (-22 to -2) -0.7 (-13.9 to 12.5) 0.864 
RDW (%) 12.7 (11.9-13.5) 13.8 (12.5-15.0) 1.0 (0.6 to 1.4) 12.5 (11.9-13.2) 13.0 (12.4-14.5) 0.8 (0.4 to 1.2) 0.2 (-0.3 to 0.8) 0.371 
MPV (fl) 8.5 (7.5-9.3) 8.1 (7.3-9.3) -0.2 (-0.5 to 0.0) 8.0 (7.3-9.3) 7.5 (6.8-8.3) -0.7 (-1.0 to -0.4) 0.5 (0.2 to 0.9) 0.007 
Plateletcrit (%) 0.183 (0.155-
0.218) 
0.163 (0.144-
0.196) 
-0.019 (-0.027 to -
0.011) 
0.184 (0.153-
0.210) 
0.161 (0.134-
0.183) 
-0.026 (-0.034 to  
-0.018) 
0.010 (0.00 to 
0.020) 
0.046 
Additional parameters         
eGFR (mL/min/1.73 m2) 71.7±22.5 61.9±25.3 -9.7 (-13.7 to 5.8) 75.8±23.4 69.9±26.0 -5.9 (-10.0 to -1.8) -4.7 (-10.2 to 0.8) 0.094 
CRP (mg/dL) 0.24 (0.10-0.69) 0.27 (0.14-0.73) 0.04 (-0.12 to 0.19) 0.21 (0.09-0.40) 0.23 (0.11-0.57) 0.02 (0.0 to 0.03) -0.08 (-0.29 to 0.13) 0.856 
1Change from baseline data is shown as means and 95% confidence interval 
1,25(OH)2D: 1,25-dihydroxyvitamin D; 25OHD: 25-hydroxyvitamin D; CRP: C-reactive protein; eGFR: estimated globular filtration rate; MCH: mean corpuscular hemoglobin; 
MCHC: mean corpuscular hemoglobin concentration; MCV: mean corpuscular volume; MPV: mean platelet volume; RDW: erythrocytes distribution width
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Figure 1:  Participant flow chart of this secondary analysis of the EVITA Trial. 
 
 
 
 
Randomized 
(n=400) 
▪ Drop-Out (n=129) 
▪ Lost-to-Follow-Up (n=40) 
▪ Death (n=54) 
Vitamin D group (n=85) Placebo group (n=87) 
Per-protocol group 
(n=177) 
Included in Data Analysis 
(n=172) 
▪ no Data on Hemoglobin 
  Levels (n=5) 
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Figure 2:  Anemia prevalence in 172 participants of the EVITA Trial at baseline and study termination; A: by study group; P-values indicate 
within study group results; B: by follow-up; P-values indicate between study group results 
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Table S1:  Results of vitamin D treatment on biochemical parameters in patients with chronic heart failure and estimated glomerular 
filtration rate values <60 mL/min/1.73 m2 
 
Vitamin D group (n=26) Placebo group (n=23) 
  
Characteristics Baseline Follow-up (36 
months) 
Mean change from 
baseline1 
Baseline Follow-up (36 
months) 
Mean change from 
baseline1 
Treatment effect P-value 
Anemic patients (%) 19.2 38.5 - 17.4 30.4 - - - 
Vitamin D metabolites         
25OHD (nmol/l) 31.5 (22.9-54.2) 79.9 (62.4-148.3) 70.5 (45.1 to 95.9) 34.7 (25.7-52.4) 38.7 (30.5-63.4) 11.8 (-1.3 to25.0) 58.6 (29.3 to 88.0) <0.001 
1,25(OH)2D (pmol/l) 74.4±41.2 86.5±27.9 12.0 (-3.7 to 27.8) 90.3±36.6 68.9±38.6 -19.2 (-36.2 to -2.1) 21.7 (3.3 to 40.1) 0.022 
Hematological parameters         
Hemoglobin (g/dL) 13.7±1.8 13.0±1.8 -0.8 (-1.5 to 0.1) 13.8±1.7 13.0±2.1 -0.8 (-1.8 to 0.2) 0.0 (-1.0 to 1.0) 0.997 
Hematocrit (%) 40.6±5.5 39.9±5.8 -0.7 (-2.9 to 1.5) 40.6±5.1 39.1±5.9 -1.5 (-4.5 to 1.5) 0.8 (-2.4 to 3.9) 0.615 
Leukocytes (109/L) 8.3 (7.6-9.7) 8.3 (6.9-9.2) -0.5 (-1.3 to 0.3) 8.8 (6.3-10.6) 7.9 (5.8-9.2) -0.8 (-1.6 to 0.1) 0.4 (-0.5 to 1.3) 0.396 
Erythrocytes (1012/L) 4.5 (3.9-4.9) 4.5 (4.1-4.9) 0.0 (-0.2 to 0.3) 4.4 (4.0-4.9) 4.2 (3.8-4.6) -2.0 (-5.8 to 1.9) 0.3 (0.0 to 0.7) 0.064 
MCV (µm3) 90.6±5.2 88.5±8.5 -2.1 (-5.2 to 1.0) 93.7±6.1 92.3±5.0 -1.4 (-3.8 to1.1) -2.1 (-5.9 to 1.7) 0.275 
MCH (pg Hb/red blood cell) 31.1 (29.1-32.1) 29.4 (26.4-31.1) -1.9 (-2.9 to -0.9) 32.5 (30.5-33.0) 30.5 (28.8-31.7) -1.2 (-2.3 to 0.1) -1.3 (-2.7 to 0.1) 0.060 
MCHC (g/L) 33.9±1.0 32.5±1.4 -1.3 (-2.1 to 0.6) 34.0±1.3 33.2±1.5 -0.8 (-1.6 to 0.0) -0.7 (-1.5 to 0.2) 0.126 
Thrombocytes (109/L) 195 (182-244) 187 (164-215) -12 (-29 to 6) 221 (195-254) 213 (170-272) -15 (-38 to 8) -6 (-33 to 20) 0.789 
RDW (%) 13.4±1.2 15.2±1.9 1.7 (-1.0 to 2.5) 13.2±1.5 14.6±2.4 1.4 (-0.4 to 2.3) 0.5 (-0.7 to 1.6) 0.428 
MPV (fl) 8.7±1.2 8.7±1.6 0.0 (-0.7 to 0.7) 8.2±1.5 7.5±1.0 -0.7 (-1.3 to -0.1) 1.1 (0.3 to 1.8) 0.008 
Plateletcrit (%) 0.188±0.042 0.170±0.035 0.019 (-0.036 to -
0.002) 
0.193±0.057 0.165±0.044 -0.031 (-0.051 to -
0.011) 
0.009 (-0.010 to 
0.029) 
0.325 
Additional parameters         
eGFR (mL/min/1.73 m2) 46.0 (39.3-52.0) 37.5 (29.8-48.0) -5.4 (-11.3 to 0.6) 48.0 (42.0-56.0) 45.0 (32.0-64.0) 0.4 (-7.2 to 7.9) -6.3 (-15.5 to 2.9) 0.195 
CRP (mg/dL) 0.29 (0.15-0.86) 0.33 (0.20-0.96) -0.12 (-0.45 to 0.21) 0.29 (0.18-0.53) 0.41 (0.21-1.20) 0.34 (-0.14 to 0.82) -0.4 (-0.9 to 0.0) 0.225 
1Change from baseline data is shown as means and 95% confidence interval 
1,25(OH)2D: 1,25-dihydroxyvitamin D; 25OHD: 25-hydroxyvitamin D; CRP: C-reactive protein; eGFR: estimated globular filtration rate; MCH: mean corpuscular hemoglobin; 
MCHC: mean corpuscular hemoglobin concentration; MCV: mean corpuscular volume; MPV: mean platelet volume; RDW: erythrocytes distribution width
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Discussion 
The present investigation indicates that a daily vitamin D supplement of 4,000 IU for 36 months 
does not improve Hb values in patients with end-stage HF. Moreover, the incidence of anemia 
increased in both groups to a similar extent. Comparable results were obtained in the subgroup 
of patients with initial eGFR values <60 mL/min/1.73 m2. 
Our data do not support results of a recent meta-analysis, reporting an inverse association of 
circulating 25OHD with anemia risk [29]. However, our data are in line with results of three 
other RCTs in subjects with concurrent iron-deficiency anemia, ethnic minorities living in 
Norway, and hypertensive patients [19,20,25]. In these earlier studies, duration ranged from 8 
to 16 weeks and vitamin D doses ranged from 400 IU to 2,800 IU daily or 600,000 IU once 
intramuscularly. Although in another small, placebo-controlled trial [21] 650,000 IU vitamin D 
(50,000/weekly over a 4-months period) significantly decreased the required dose of EPO, no 
correlation between Hb levels and 25OHD concentrations could be shown. Moreover, it 
remains unclear why in that RCT 20 out of the 64 study subjects were excluded from data 
analysis. The required ESA dose was also reduced in a small RCT in children with CKD stage 
5, who received vitamin D2 or placebo in conjunction with oral alfacalcidol (0.25 µg/capsule) 
for 12 weeks [18]. Unfortunately, no data on circulating 1,25(OH)2D levels were presented. 
1,25(OH)2D has been shown to stimulate erythroid precursor proliferation via increased 
erythropoietin sensitivity [30]. Some earlier observational studies reported that compared with 
the reference category of circulating 1,25(OH)2D levels >70 pmol/l, the multivariable-adjusted 
odds ratio for anemia was 2.35 to 4.08 in the categories of circulating 1,25(OH)2D levels <40 
pmol/l [2,11,12]. In the present RCT, the treatment effect on circulating 1,25(OH)2D was on 
average +17.1 pmol/l. The increment is in line with a recent meta-analysis reporting that 
vitamin D supplements increase circulating 1,25(OH)2D on average by +18.8 pmol/l (95% CI: 
9.2 to 28.4 pmol/l) [31], but was probably too small to achieve significant effects on anemia 
risk. It might also be that in the present RCT the average initial 1,25(OH)2D level of 81.6 pmol/l 
was already above the threshold for stimulating erythropoiesis. It is also noteworthy that 
anemia risk is associated with the severity of the HF [4,23,32,33], Therefore, there may simply 
be no causal relationship between vitamin D status and anemia in end-stage HF. This 
assumption is further supported by the fact that even in the subgroup of patients with eGFR 
values <60 mL/min/1.73 m2, where EPO production and circulating 1,25(OH)2D levels are 
reduced, vitamin D treatment had no effect on Hb levels and anemia risk. 
Vitamin D treatment increased MPV and plateletcrit and decreased MCHC values significantly. 
High MPV and plateletcrit values are associated with acute myocardial infarction [34] and long 
term mortality in patients non-ST-segment elevation myocardial infarction [35]. Since median 
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values of both MCHC and plateletcrit were still in the reference range, we conclude that the 
vitamin D-mediated treatment effects are not clinical relevant.  
Our study has several strengths, but also some limitations. Strengths are the study design, the 
large number of study participants, the study duration of 36 months, and the measurement of 
the active hormonal form of vitamin D, 1,25(OH)2D, in addition to circulating 25OHD levels. 
One limitation is that we have no data on nutritional risk factor of anemia such as folate or 
vitamin B12 deficiency. Another limitation is that the study population was restricted to 
Caucasian ethnicity.  
In summary, the present study was unable to show significant effects of a daily vitamin D 
supplement of 4,000 IU for 36 months on Hb values and anemia risk in patients with end-stage 
HF. Our data challenge the clinical relevance of vitamin D supplementation to increase Hb 
levels. 
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The aim of this thesis was to investigate the associations between vitamin D metabolites and 
anemia risk in patients with CVD and to examine if these associations are causal by analyzing 
data of two RCTs. The first cross-sectional study (CHAPTER ONE) investigated the associations 
between the vitamin D metabolites 25OHD and 1,25(OH)2D with preoperative anemia (Hb 
<12.5 g/dL) in 3,615 patients scheduled for cardiac surgery. In the second cross-sectional 
study (CHAPTER TWO) the same associations were investigated in 3,299 patients referred for 
coronary angiography. In two secondary analyses of RCTs, we examined if these associations 
were causal: The first interventional study (CHAPTER THREE) investigated whether a vitamin D3 
supplementation of 2,800 IU daily for eight weeks can improve Hb levels and reduce anemia 
risk in 200 hypertensive patients compared to a matching placebo. The second investigation 
(CHAPTER FOUR) examined the impact of a vitamin D3 supplementation of 4,000 IU daily versus 
placebo for 36 months on Hb levels and therefore anemia risk in 172 heart failure patients. In 
both interventional trials, patients had initial 25OHD levels below 75 nmol/l. 
Both cross-sectional studies demonstrate an independent inverse association between vitamin 
D status and anemia risk in patients with CVD (CHAPTER ONE and CHAPTER TWO). In cardiac 
surgical patients and patients referred to coronary angiography with deficient 25OHD levels 
(<30 nmol/l) mean Hb levels were 0.5 g/dL and 0.6 g/dL lower than in patients with adequate 
levels (50-125 nmol/l), respectively. Regarding 1,25(OH)2D, mean Hb concentrations were 1.2 
g/dL and 1.3 g/dL lower in the lowest 1,25(OH)2D category (<40 pmol/l) compared to the 
highest 1,25(OH)2D category (>70 pmol/l). In both studies, multivariable adjusted logistic 
regression analyses showed that the ORs for anemia of the lowest categories of 25OHD (<30 
nmol/l) and 1,25(OH)2D (<40 pmol/l) were significantly higher compared with patients who had 
adequate 25OHD levels (50-125 nmol/l) and 1,25(OH)2D values in the highest category (>70 
pmol/l). In both studies, these associations were stronger for 1,25(OH)2D than 25OHD and 
anemia risk was highest in patients with dual deficiency. 
Our results regarding the association between 25OHD status and anemia risk are in line with 
findings from observational studies conducted in various groups of individuals [1-13]. These 
studies included patients with CVD, e.g. cardiac surgical patients [14] and patients with heart 
failure [15], also demonstrating an independent association of anemia risk with low 25OHD 
concentrations. In accordance with these data, a recent meta-analysis of observational studies 
showed that vitamin D deficiency (<75 nmol/l or 50 nmol/l) was associated with an increased 
incidence of anemia (OR=2.25 [1.47-3.44]), compared with individuals with adequate vitamin 
D status [16]. In contrast to the broad availability of data regarding the association between 
25OHD and anemia risk, the association of 1,25(OH)2D with anemia risk has rarely been 
studied. The few available studies have been conducted in patients with heart failure, older 
Australian men and patients with CKD. In regard to the study also examining heart failure 
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patients, results are in line with our study, showing that the association was stronger for 
1,25(OH)2D concentrations than for circulating 25OHD concentrations [15]. In a study 
examining 1,666 older men, only 1,25(OH)2D levels, but not 25OHD levels, were significantly 
associated with Hb levels [17]. This difference may be, at least to some extent, due to the 
smaller number of individuals studied by Hirani et al. and the lower statistical power to achieve 
significant results. In contrast, in patients with CKD, the association between 25OHD and 
anemia was found to be stronger than between 1,25(OH)2D and anemia [8]. 
However, although statistical adjustments were performed to preclude some sources of bias, 
the observational study design of CHAPTER ONE and CHAPTER TWO does not allow a 
confirmation of a causal relationship between vitamin D and anemia. Therefore, two secondary 
analyses of RCTs were performed to examine if vitamin D deficiency is a factor in the etiology 
of anemia in patients with CVD. 
Both investigations (CHAPTER THREE and CHAPTER FOUR) indicate that compared to placebo, 
a daily vitamin D supplement does not improve Hb values in patients with CVD. In hypertensive 
patients (CHAPTER THREE), a daily vitamin D supplementation of 2,800 IU for eight weeks 
resulted in a mean treatment effect on Hb levels of 0.04 (-0.14 to 0.22) g/dL (P=0.661). Thus, 
vitamin D treatment did not influence anemic status significantly. In the vitamin D group, 7.5% 
of patients were anemic at baseline and study termination (>0.999). In addition, vitamin D had 
no effect on other hematological parameters. Since patients with deficient vitamin D status 
(<30 nmol/l) had the lowest Hb levels and the highest risk of being anemic in CHAPTER ONE 
and CHAPTER TWO, a subgroup analysis in the group of patients with initial 25OHD levels <30 
nmol/l was conducted. Again, there was no vitamin D effect on Hb levels. However, with eight 
weeks, the study duration was relatively short, given that it usually takes approximately three 
months to reach a steady state in circulating 25OHD levels [18] and that the half-life of red 
blood cells in circulation is also three months. In addition, prevalence of anemic patients and 
patients with 25OHD levels <30 nmol/l at baseline was low and no measurement of 1,25(OH)2D 
was conducted. Since both observational studies included in this thesis showed that the 
association with anemia risk was stronger for 1,25(OH)2D concentrations than for circulating 
25OHD concentrations and, among others, 1,25(OH)2D has been shown to stimulate erythroid 
precursor proliferation by increasing EPO sensitivity (INTRODUCTION) , this measurement is of 
great interest. 
Therefore, in CHAPTER FOUR, a post-hoc analysis in the per-protocol population of an RCT with 
a daily vitamin D supplement of 4,000 IU for a study duration of 36 months and a higher initial 
prevalence of anemia (11.6%) including 1,25(OH)2D measurement was conducted. However, 
the investigation confirms the main result of CHAPTER THREE: A daily vitamin D supplement of 
4,000 IU for 36 months does not improve Hb values. In fact, the incidence of anemia increased 
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in both groups from 11.6% to a similar extent, leading to an overall anemia prevalence of 
23.3%. Therefore, mean treatment effect on Hb levels was -0.04 (-0.53 to 0.45) g/dL (P=0.865). 
Regarding circulating 1,25(OH)2D, the mean treatment effect was +17.1 (6.2 to 27.9) pmol/l 
(P=0.004), which is in line with a recent meta-analysis showing that vitamin D supplementation 
increase 1,25(OH)2D levels on average by +18.8 (9.2 to 28.4) pmol/l [19]. However, the 
increase may have been too small to achieve significant effects on anemia risk. Although the 
reference range for circulating 1,25(OH)2D levels is not yet well defined, the Gaussian 
distribution of apparently healthy individuals assume a reference interval of 38 to 134 pmol/l 
with a mean value of 90 pmol/l [19,20]. Possibly, the average initial 1,25(OH)2D level of 81.6 
pmol/l was already above the threshold for stimulating biological actions reducing anemia risk 
e.g stimulating erythropoiesis. Therefore, a subgroup analysis including only patients with 
eGFR values <60 mL/min/1.73 m2 who have reduced EPO production and circulating 
1,25(OH)2D levels, was performed (CHAPTER FOUR, Supplemental Table 1). Again, vitamin D 
treatment had no effect on Hb levels and anemia risk. 
Our results are in line with other recent RCTs. Madar et al. did not find a difference in change 
of Hb values between those receiving oral vitamin D3 supplementation (400 or 1,000 IU/d 
combined) or those receiving placebo after 16 weeks in healthy ethnic minorities living in 
Norway [21]. In this cohort, 90% of the study subjects had initial 25OHD concentrations of <50 
nmol/l. However, although the vitamin D doses used were sufficient to increase the 25OHD 
levels, it failed to increase the 25OHD levels above 50 nmol/l in 43% of the 1,000 IU 
supplementation group and in 62% of the 400 IU supplementation group [21]. In contrast, with 
25OHD concentrations of 90.3 nmol/l and 92.1 nmol/l at study termination, adequate circulating 
levels (50 to 125 nmol/l) were reached in our study cohorts of hypertensive patients and 
patients with heart failure, respectively. Therefore the scenario that the given vitamin D 
dosages were too low to reach sufficient 25OHD concentrations can be ruled out. Another 
randomized, single-blinded, placebo-controlled 12-week trial in vitamin D deficient subjects 
with iron-deficiency also failed to show a significant difference in Hb values between groups 
after one intramuscularly dose of 600,000 IU vitamin D3 [22]. Naini et al. showed that 650,000 
IU vitamin D over a 4-months period (50,000/weekly) significantly decrease the required dose 
of EPO compared to placebo [23]. However, there was no correlation between the Hb levels 
and 25OHD concentrations. In children with CKD stage 5, oral vitamin D2 treatment for 12 
weeks significantly decreased the required dose of ESA [24].  
Although recent RCTs, including CHAPTER THREE and FOUR, failed to demonstrate significant 
Hb-improving effects of vitamin D supplementation, first non-randomized interventional studies 
in patients with CKD demonstrated an increase in Hb levels after 12 months of intravenous 
1,25(OH)2D administration, resulting in improved control of anemia with reduced need for EPO 
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[25,26]. In a prospective study examining the effect of high-dose alfacalcidol (1α-
hydroxyvitamin D) in anemic hemodialysis patients, Hb levels increased significantly by 2.0 
g/dL and 1.8 g/dL at 12 and 18 months, respectively. Of note, initial Hb levels were 8.7 g/dL 
[27]. In the other two aforementioned studies, initial Hb values were 10.7 g/dL and 10.2 g/dL, 
respectively [25,26]. In our study cohorts, initial Hb values were 14.4 g/dL and 14.2 g/dL, 
respectively. Thus, with 6.5 % (CHAPTER THREE) and 11.6 % (CHAPTER FOUR), the prevalence 
of anemic patients at baseline was low. Possibly, the missing effects can be explained by the 
aforementioned Hb levels which are already within the reference range of 13.5-17.5 g/dL for 
men and 12-16 g/dL for women. Therefore, it may be a possible explanation that the initial Hb 
levels of both study cohorts were too high and the prevalence of anemic patients too low to 
achieve any improving effects on Hb levels. Nevertheless, these first interventional studies 
have some limitations since they included only small numbers of participants and had no 
control group. In these non-randomized studies the administered vitamin D were active 
metabolites. In contrast, we used vitamin D3 supplements in both interventional studies.  
The investigations of this thesis have several strengths, but also some limitations. Strengths 
are (1) the large number of included patients in all four studies, (2) the measurement of the 
active vitamin D metabolite, 1,25(OH)2D, in three out of the four studies and (3) the 
performance of multivariable-adjusted analyses including important confounders conducted in 
CHAPTER ONE and CHAPTER TWO. Regarding CHAPTER THREE and CHAPTER FOUR the 
strengths are (4) the randomized, placebo-controlled study design, the fact that (5) only 
patients with relatively low circulating 25OHD levels were included and (6) the daily vitamin D 
doses, which were sufficient to increase in-study 25OHD levels distinctly above 75 nmol/l on 
average. The included studies also have some limitations. First, the findings are restricted to 
selected study cohorts of Caucasian participants with CVD. Therefore, the results may not be 
generalizable to other study populations. Second, regarding the study design of CHAPTER 
THREE and CHAPTER FOUR, two secondary analyses of RCTs were conducted. Therefore, 
clinical studies investigating change in Hb levels as the primary endpoint are still warranted. 
Third, in none of the included studies data on nutritional risk factors such as folate or vitamin 
B12 deficiency as well as reticulocytes, EPO concentrations and use of ESA was available. 
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In conclusion, despite the broad range of encouraging observational studies including 
CHAPTER ONE and CHAPTER TWO of this thesis, results of recent RCTs including CHAPTER 
THREE and CHAPTER FOUR do not support a causal relationship between vitamin D 
supplementation and anemia risk. It may be that both, anemia and vitamin D deficiency, are 
markers of progressive health status rather than causal factors depending on each other. 
Overall, this thesis argues against clinically relevant Hb-improving effects of vitamin D3 
supplements in patients with CVD. However, given the study design, studies investigating the 
effect of vitamin D supplementation or administration on Hb levels in vitamin D deficient 
individuals as primary endpoint are still warranted. Furthermore, since there is a stronger 
independent association between 1,25(OH)2D concentrations and anemia risk than between 
25OHD levels and anemia risk and first interventional studies using 1,25(OH)2D administration 
showed promising results, future studies should explore the administration of active vitamin D 
metabolites in anemic and vitamin D deficient patients in more detail.  
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